THE MAIN TEA ETA US 20180036360A1MAI MULT LA MA MA MAIT ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0036360 A1 Wilmanowicz (43 ) Pub . Date: Feb . 8 , 2018 (54 ) IMMUNOLOGICALLY ACTIVE A61K 36 /32 (2006 .01 ) PHYTO -MIXTURE AND ITS USE IN THE A61K 36 /68 (2006 . 01) PREVENTION AND IN A METHOD FOR (52 ) U . S . CI. TREATMENT OF EFFLORESCENCES CPC ...... A61K 36 / 28 (2013 .01 ) ; A61K 36 / 32 (2013 .01 ) ; A61K 36 /68 (2013 .01 ); A61K 36 /85 (71 ) Applicant : Renate Wilmanowicz , Düsseldorf (DE ) ( 2013 .01 ) ; A61K 36 / 886 ( 2013 . 01 ) ; A61K 8 / 97 ( 72 ) Inventor : Renate Wilmanowicz , Düsseldorf (DE ) ( 2013. 01 ) (57 ) ABSTRACT ( 21 ) Appl. No. : 15 /550 , 600 The present invention relates to an immunologically active (22 ) PCT Filed : Feb . 10 , 2016 phyto -mixture comprising at least one plant extract selected from the family a ) Asteraceae , b ) Verbenaceae, and / or c ) ( 86 ) PCT No .: PCT/ EP2016 / 052836 Burseraceae , preferably at least one plant extract from the genus a ) Bidens , b ) Stachytarpheta , and / or c ) Bursera . $ 371 ( C ) ( 1 ), Particularly preferred species include a ) Bidens alba , Bidens ( 2 ) Date : Aug . 11 , 2017 pilosa , b ) Stachytarpheta jamaicensis , Stachytarpheta cay ennensis , Stachytarpheta indica , and /or c ) Bursera (30 ) Foreign Application Priority Data simaruba , Bursera microphylla , Bursera glabrifolia . The phyto -mixture optionally comprises d ) at least one further Feb . 12, 2015 (DE ) ...... 10 2015 102 020 .3 biologically active plant extract, such as Aloe vera and /or Stemodia maritima . The afore -mentioned phyto -mixture Publication Classification according to the invention exhibits good antimicrobial and (51 ) Int. Ci. anti - inflammatory efficiency and is particularly suitable for A61K 36 / 28 ( 2006 . 01 ) prevention and treatment of efflorescences . Therefore , the A61K 8 / 97 ( 2006 .01 ) present invention also relates to a preparation for oral and A61K 36 /85 ( 2006 .01 ) topical administration for prevention and treatment of efflo A61K 36 / 886 ( 2006 . 01 ) rescences of the skin and the mucous membrane. US 2018 /0036360 A1 Feb . 8 , 2018

IMMUNOLOGICALLY ACTIVE ucts, such as plant extracts , shall be provided , which may PHYTO -MIXTURE AND ITS USE IN THE individually be mixed for the user . A further object is the PREVENTION AND IN A METHOD FOR provision of a phyto -mixture for the production of prepara TREATMENT OF EFFLORESCENCES tions for preventive use or therapeutic use in the treatment 10001 ] The present invention relates to an immunologi of efflorescences . For this purpose , pharmaceutic composi cally active phyto - mixture comprising at least one plant tions , care products , nutritional supplements , as well as extract selected from the family a ) Asteraceae, b ) Verben medical products comprising a phyto -mixture from total aceae, and / or c ) Burseraceae , preferably from the genus a ) extracts of plants shall be provided . Moreover , the present Bidens, b ) Stachytarpheta , and /or c ) Bursera . Particularly invention provides the object of providing a natural product preferred species include a ) Bidens alba , Bidens pilosa , b ) as alternative to synthetically produced products . The object Stachytarpheta jamaicensis , Stachytarpheta cayennensis , is to provide a natural product from plant sources , in Stachytarpheta indica , and / or c ) Bursera microphylla , Burs particular for humans , in which the synthetically produced era glabrifolia and Bursera simaruba . The phyto -mixture products known from the state of the art exhibit strongly optionally comprises d ) at least one further biologically reduced or no more efficiency and /or increasingly cause side active plant extract , such as Aloe vera and /or Stemodia effects . The afore -mentioned plant products and their prepa maritima . The afore -mentioned phyto -mixture according to rations comprising the phyto -mixture shall be provided for the invention exhibits good antimicrobial and anti - inflam prevention and treatment of efflorescences. matory efficiency and is particularly suitable for prevention [0008 ) The present invention therefore provides a natural and treatment of efflorescences . Therefore , the present product from plant sources, having both antimicrobial, pref invention also relates to a preparation for oral and topical erably antibacterial, and anti - inflammatory effect . administration for prevention and treatment of efflores [0009 ]. Therefore , a subject matter of the present invention cences of the skin and the mucous membrane . is an immunologically active phyto -mixture comprising at [0002 ] In modern medicine , comprehensive synthetically least one plant extract selected from produced pharmaceutical products for prevention or treat [ 0010 ] a ) the species Bid . alba , Bid . pilosa , Bid . bipin ment of skin irritations and skin diseases are provided for the nata and Bid . parviflora , preferably Bidens alba and /or patients . These are prescribed by the doctor as authorised Bidens pilosa , from genus Bidens of the Asteraceae medicaments or are available as nonprescription medical family , products . However, due to synthetic active agents , the [0011 ] b ) the species Stachytarpheta jamaicensis , pharmaceutic compositions increasingly cause side effects , Stachytarpheta indica and Stachytarpheta cayennensis cause allergic reactions or result in steadily growing resis from genus Stachytarpheta of the Verbenaceae family , tances in infection germs causing the skin irritations or and /or diseases . [ 0012 ] c ) the species Bursera microphylla , Bursera 10003 ]. Therefore , there are more and more aspirations for glabrifolia and /or Bursera simaruba from genus Burs isolating new active agents , continuously having efficiency era of the Burseraceae family , and against resistant germs, causing few or no side effects or optionally , additionally d ) at least one further extract of a allergic reactions in human , and potentially having an biologically active plant, as described below . improved resorption in human . For this purpose , microor [0013 ]. In the case where the wording “ plant extracts a ), b ) , ganisms itself or plants may be used as source of new acting and /or c ) " is used without limitation to a specific species , it agents . shall be understood to mean an abbreviation of the afore [0004 ] In the case of plant sources , some compound mentioned wording . In the following, the name of the classes , such as, for example flavones , are isolated and appropriate genus is abbreviated a ) Bidens by “ Bid .” , b ) processed into pharmaceutic preparations . RU2412719 dis Stachytarpheta by " Sta . ” , and c ) Bursera by “ Bur. ” . closes such flavone extracts for medicaments for treatment [0014 ] Preferably , the afore -mentioned plant extracts are of liver diseases . CN102743651 discloses a mixture of 30 aqueous or ethanolic extracts (greater than or equal to 70 % different plants in the form of a lotion for treatment of ethanol, remainder water ) cellulitis . [0015 ] The “ immunologically active phyto -mixture ” 10005 ] In the state of the art, miscellaneous plants , in according to the invention is briefly , thus synonymously , particular from traditional medicine , are tested for their termed as “ phyto -mixture ” . efficiency , their ingredients are identified , the toxicity is 10016 ) Within the meaning of the invention , " immuno analysed , but only less or no efficiency is observed logically active ” means that the phyto -mixture according to ( EP114709A1) . the invention , in particular the contained ingredients and [ 0006 ] Previously , only few analyses have been performed compounds , prevents , inhibits or reduces immune reactions for plant preparations and no one has both antibacterial and of the body. “ Immunologically active” comprises preventive anti- inflammatory efficiency . Consequently , no plant alter effect so that immune reactions of the body are not even native to synthetic active agents , such as, for example being triggered , and therapeutic effect so that the already antibiotics , or synthetic inflammation inhibitors has previ triggered immune reactions in the body are stopped , down ously been detected . regulated or reduced . Depending on administration time, the [0007 ] The present invention provides the object of pro beginning immune reaction may be inhibited prior to occur viding new preparations having effective ingredients from ring of symptoms, accompanying with immune reaction , and natural sources, in particular effective ingredients of plant phenotypic appearances . Endogenous microorganisms, sources. A further object is to provide a plant product and pathogens influencing in /on the body , such as bacteria , preparations having antimicrobially , preferably antibacteri viruses, fungi and parasites , or toxic and / or influencing ally , and / or anti - inflammatorily effective ingredients . In this compounds triggering allergic reactions may be trigger of context, various possible combinations of some plant prod the afore -mentioned immune reactions . US 2018 /0036360 A1 Feb . 8 , 2018

[ 0017 ]. The immune response of the immune system to an arranged at the head of a twig or stem . Further features organism , in particular microorganisms, or substance , in distinguishing from Bid . pilosa are known by the person particular toxins, is termed as immune reactions. skilled in the art. [0018 ] What triggers the afore -mentioned immune reac [0026 ] The afore- mentioned Bidens species comprise fla tion depends on constitution of the organism , human or vonoids, luteolin , terpenes, polyacetylenes, phenylheptratri animal. Thus, a distinction is to be made between healthy yne (PHT ) , phenylpropanoids, in particular anethole , apiol, organism and immunosuppressive organism . cinnamic aldehyde , dillapiole and estragole , lipids and ben [0019 ] A healthy organism , in particular human , has no zoids as secondary plant substances , and exhibit, according congenital disease , in particular no immune weakening to the invention , antimicrobial, preferably antibacterial and / disease , thus having a normally working and reacting or antimycotic , as well as anti - inflammatory efficiency . immune system . [ 0027 ] Within the meaning of the invention , the Bidens species according the invention , preferably Bid . alba and /or [0020 ] An immune weakened organism , in particular Bid . pilosa , exhibit antimicrobial, in particular at least immune weakened human , has a weakened immune system . antibacterial, efficiency against transient skin flora compris Weakening may occur by a temporary disease , such as ing staphylococcus , streptococcus, methicillin -resistant influenza or common cold , a long - lasting disease, such as Staphylococcus aureus (MRSA ) , pseudomonads and /or cancer, malnourishment/ undernourishment, infections with acinetobacteria . The Bidens species according to the inven certain pathogens , as well as intake of certain medications , tion , preferably Bid . alba and /or Bid . pilosa , particularly e . g . chemotherapeutics , or radiation . The afore -mentioned preferably exhibit antibacterial efficiency against Staphylo weakening is an acquired immunodeficiency which has to be coccus aureus ( ATCC 25923 ) , Staphylococcus epidermidis distinguished from congenital immunodeficiency. Congeni ( ATCC 14990 ), MRSA (NCTC 10442) , Pseudomonas tal immune deficiency is based on mutations in genes aeruginosa ( ATCC 27853 ) and Acinetobacter baumanii impairing , for example, the production or function of anti ( ATCC BAA 747) ( Example 7 ). bodies or phagocytes which are related to T - cell or B -cell [0028 ] In particular , antimicrobial, preferably antibacte dominated immune response . rial, efficiency is achieved by plant extracts of a Bidens [0021 ] The present invention preferably relates to an species , preferably Bid . alba and /or Bid . pilosa , which immunologically active phyto -mixture being suitable pre comprise compounds being active against microorganisms, ventively or for treatment of efflorescences in healthy in particular gram -positive and / or gram -negative bacteria , humans and acquired immune weakened human . comprising centaurein , centauredin , polyacetylene , phenyl [0022 ] In a further embodiment, the immunologically heptatriyne ( PHT) , polyyne , 1, 2 - dihydroxytrideca - 3 , 5 , 7 , 9 , active phyto mixture according to the invention optionally 11 -pentayne . comprises additionally d ) at least one further extract of a 10029 ]. Within the meaning of the invention , the afore biologically active plant comprising Aloe species of genus mentioned Bidens species exhibit , additionally to the anti Aloe of the Asphodeloideae subfamily , species of genus microbial, in particular antibacterial, efficiency , anti - inflam Stemodia (briefly “ Stem .” ) of the Plantaginaceae family and matory efficiency at less than or equal to 200 + 10 ug /ml of Stem . maritima . Preferred Aloe species include Aloe vera , the respective plant extract, preferably less than or equal to Aloe barbadensis , Aloe perfoliata , Aloe vulgaris, Aloe 180 + 10 ug /ml , less than or equal to 160 + 10 ug/ ml , less than indica and Aloe chinensis . or equal to 140 + 10 ug /ml , particularly preferably less than [0023 ] The Asteraceae family comprises the a ) genus or equal to 130 - 10 ug /ml , and less than or equal to 110 - 10 Bidens ( = A ) comprising miscellaneous Bidens species also ug /ml measured as IC50 der 5 - LOX inhibition . referred to colloquially as “ Beggartick ” . Genus Bidens had [ 0030 ] In particular, anti- inflammatory efficiency is formerly been assigned to the Compositae family by the achieved by plant extracts of a Bidens species , preferably person skilled in the art. Genus Bidens comprises the species Bid . alba and / or Bid . pilosa , which comprise compounds Bid . alba , Bid . pilosa , Bid . aurea , Bid . beckii, Bid . bipinnata , being active against 5 -lipoxygenase , comprising triterpenes, Bid . biternata , Bid . parviflora , Bid . connata and Bid . tri flavonoids, aurones , chalcones , luteolin , 1 -phenyl - 1 , 3 - di partita . Species Bid . alba , Bid . pilosa , Bid . bipinnata and yne - 5 -en - 7 -ol - acetate , caffeates and ethyl caffeates . Bid . parviflora are use according the invention . Species Bid . [ 0031 ] The Verbenaceae family , also referred to as vervain alba and Bid . pilosa are preferred , and Bid . alba is particu family , comprises about 35 genera . The b ) genus Stachytar larly preferred as a plant extract in the phyto -mixture . pheta ( B ) comprises the species Sta . angustifolia , Sta . [0024 ] Distinction between the mentioned species is pref cayennensis , Sta . chamissonis, Sta . glauca, Sta . glabra , Sta . erably made with young and full - grown plants having dif jamaicensis, Sta . indica , Sta . mutabilis , Sta . steyermarkii, ferentiated growth and which already have fruit organs, such Sta . svensonii and Sta . urticaefolia . Sta . cayennensis , Sta . as buds and blossoms, and leaves and blossoms differenti jamaicensis and Sta . indica are species within the meaning ated in colour and shape . Preferably , one - to four- years -old , of the invention , and Sta . jamaicensis is particularly pref particularly preferably one - to three - years- old , plants are erably in the phyto -mixture according to the invention as a used . plant extract. [ 0025 ] Differentiated plants of the species Bid . alba and [0032 ] The afore -mentioned Stachytarpheta species com Bid . pilosa distinguish in growth height, wherein Bid . alba prise the ingredients 3 , 4 - dihydroxycinnamic acid (caffeic has a smaller maximal growth height of up to 2 m than Bid . acid ) , flavonoids, saponins, tannins, phenols , steroids, in pilosa . The blossoms of Bid . alba are small and have a radial particular scutellarin and hispidulin , terpenes, phenylpro symmetry and have an appearance similar to the daisies panoids, in particular verbascosides ( also referred to as having yellow pollen in the center of the blossom and five , acteosides ), glycosides , in particular phenylethanoid glyco in particular white , petals . The blossoms are always sides , phenylpropanoid glycosides , iridoids, iridoid glyco US 2018 /0036360 A1 Feb . 8 , 2018

sides , ipolamiides, tarphetalin , and 4 -methoxycarbonyl - 7 Bur. simaruba is particularly preferred as a plant extract in methylcyclopenta [ c ]pyran ( fulvoipolamiides) . the phyto -mixture according to the invention . [ 0033] Verbascosides are phenylethanoid glycosides being an ester of phenylethanoid hydroxytyrosol, phenylethanoid [0040 ] Within the meaning of the invention , the plant 3 ,4 -dihydroxycinnamic acid and the sugar alpha -L - rhamn extracts of the Bursera species according the invention opyranosyl - ( 1 - 3 ) -beta - D - glycopyranose. exhibit good antimicrobial, at least antibacterial, efficiency [ 0034 ] Stachytarpheta species comprise the compounds against transient skin flora comprising , in particular, staphy verbascosides , flavonoids, glycosides, phenylethanoid and lococcus, streptococcus, methicillin -resistant Staphylococ phenylpropanoid glycosides and anthraquinones as antimi cus aureus (MRSA ), pseudomonads and /or acinetobacteria . crobially , preferably antibacterially and/ or antimycotically , Bur. simaruba , Bur. microphylla and /or Bur. glabrifolia are effective compounds . effective against Staphylococcus aureus (ATCC 25923 ) , [ 0035 ] Stachytarpheta species comprise verbascosides , Staphylococcus epidermidis (ATCC 14990 ), MRSA (NCTC flavonoids, iridoids, ipolamiides , iridoid ipolamiides, acteo 10442 ) , Pseudomonas aeruginosa (ATCC 27853 ) and sides , fulvoipolamiides, sesquiterpene lactones and proazu Acinetobacter baumanii (ATCC BAA 747 ) ( Example 7 ) . lenes as anti - inflammatorily effective compounds. Said com pounds are particularly present in the leaves of the [0041 ] Within the meaning of the invention , the Bursera Stachytarpheta species according to the invention . There species according to the invention have , preferably , addi fore , within the meaning of the invention , plant parts com tionally to the antimicrobial efficiency, anti- inflammatory prising the afore -mentioned compounds, in particular the efficiency at less than or equal to 200 + 10 ug /ml of the leaves , are preferably used for the production of a plant respective plant extract , preferably less than or equal to extract, of Sta . jamaicensis , Sta . indica and / or Sta . cayen 180 : 10 ug/ ml , less than or equal to 160 : 10 ug/ ml , less than nensis . The afore -mentioned plant extract is preferably or equal to 140 + 10 ug /ml , particularly preferably less than obtained as ethanolic plant extract having greater than or or equal to 135 + 10 ug /ml , less than or equal to 125 - 10 equal to 70 % ethanol. ug /ml , less than or equal to 80 + 10 ug /ml measured as IC50 [0036 ] Surprisingly , significant anti - inflammatory effi der 5 -LOX inhibition . ciency has respectively been proved for Bid . alba , Sta . [0042 ] Antibacterial efficiency has surprisingly been jamaicensis and Bur. simaruba as respective representatives detected for Sta . jamaicensis and Bid . alba , as well as Stem . of the species according to the invention of a ) , b ) and c ) maritima ( see Example 7) . In particular , the afore -men (Example 6 , Table 2 ) . This efficiency may be attributed to tioned species exhibit significant efficiency against gram the compounds , being contained in the species according to positive bacteria and particularly against MRSA . Thus, the the invention and being extracted by means of the method phyto -mixtures according to the invention , described herein , according the invention , comprising verbascosides, fla exhibit at least antibacterial and, preferably , additionally vonoids, iridoids , ipolamiides , fulvoipolamiides, sesquiter anti - inflammatory efficiency . pene lactones , polyacetylenes and /or proazulenes. [0043 ] A phyto -mixture made of a plant extract of a ) Bis. 0037 ] Within the meaning of the invention , the plant alba and /or Bid . pilosa and of a plant extract of b ) Sta . extracts of the Stachytarpheta species according the inven jamaicensis , Sta . cayennensis and /or Sta . indica is a par tion exhibit good antimicrobial, at least antibacterial, effi ticularly preferred combination within the meaning of the ciency against transient skin flora comprising , in particular , invention . The afore -mentioned combinations surprisingly staphylococcus, streptococcus, methicillin - resistant Staphy exhibit increased antibacterial as well as anti - inflammatory lococcus aureus (MRSA ) , pseudomonads and /or acineto efficiency (Examples 2 to 8 ). Particularly surprisingly , bacteria . Sta . cayennensis , Sta . jamaicensis and / or Sta . double efficiency has been observed for all afore -mentioned indica particularly exhibit antibacterial efficiency against preferred species . The experiments described herein exem Staphylococcus aureus (ATCC 25923 ) , Staphylococcus epi plary summarize the described efficiencies for the respective dermidis (ATCC 14990 ) , MRSA ( NCTC 10442 ) , species according to the invention of genus a ) Bidens, b ) Pseudomonas aeruginosa (ATCC 27853 ) and Acinetobacter Stachytarpheta , and c ) Bursera . baumanii ( ATCC BAA 747) (Example 7 ). [ 0038 ] Within the meaning of the invention , the Stachytar [ 0044 ] An embodiment of the phyto -mixture according to pheta species according to the invention have , preferably, the invention comprising the respective combination of plant additionally to the antimicrobial, preferably antibacterial extracts , preferably ethanolic and dry extracts , of and / or antimycotic, efficiency, anti - inflammatory efficiency a ) Bidens alba and /or Bidens pilosa and at less than or equal to 200 + 10 ug /ml of the respective plant extract, preferably less than or equal to 180 : 10 ug/ ml , less b ) Stachytarpheta jamaicensis ; or than or equal to 160 : 10 ug/ ml, less than or equal to 140 + 10 b ) Stachytarpheta jamaicensis and ug /ml , less than or equal to 120 : 10 ug /ml , particularly preferably less than or equal to 100 + 10 ug /ml , less than or c ) Bursera simaruba equal to 85 : 10 ug /ml , less than or equal to 80 + 10 ug/ ml surprisingly exhibits anti - inflammatory efficiency of less measured as IC50 der 5 - LOX inhibition . than or equal to 90 - 10 ug /ml , preferably at less than or equal [ 0039 ] The Burseraceae family comprise subtribe Burs to 70 : 10 ug/ ml and particularly preferably at 50 : 10 ug/ ml erinae to which the c ) genus Bursera ( = C ) is assigned . measured as IC 50 of 5 - LOX inhibition ( Table 3 ) . The afore Genus Bursera comprises about 100 species comprising Bur. mentioned phyto mixture exhibits , deviating from expecta bipinnata , Bur. fagaroides, Bur. glabrifolia , Bur. malacoph tions, good antimicrobial, in particular antibacterial, effi ylla , Bur. microphylla , Bur. bolivarii, Bur. trifoliolata and ciency at the same time ( Table 5b ) . The other species Bur. simaruba . Bur. simaruba , Bur. microphylla and/ or Bur. according to the invention a ), b ), and c ) exhibit appropriate glabrifolia are used within the meaning of the invention efficiencies as listed above . US 2018 /0036360 A1 Feb . 8 , 2018

[0045 ] An embodiment of the phyto -mixture according to TABLE la the invention comprising the combination of plant extracts , Optional Optional preferably ethanolic and subsequently dried extracts , of Extract preferred preferred a ) Bidens alba and c ) Bursera simaruba combination Preferred species species of species of exhibits anti -inflammatory efficiency of less than or equal to A - E / B - E Bid . albal C - E D1 and / or D2 90 + 10 ug /ml , preferably at less than or equal to 80 - 10 ug /ml Sta . jamaicensis measured as IC50 of 5 -LOX inhibition ( Table 3 ) . The afore A - E / C - E Bid albal B - E D2 = mentioned phyto mixture exhibits good antimicrobial, in Bur. simaruba Aloe vera particular antibacterial , efficiency at the same time. The B - E / C - E Sta . jamaicensis A - E D1 = Bur. simaruba Stem . maritima other species according to the invention of genus a ) Bidens and, optionally, D2 and c ) Bursera respectively exhibit appropriate efficiencies . A - E / D1 - E Bid . albal B - E D2 Stem . maritima [0046 ] Particularly preferred combinations of a ), b ), and / B - E / D1 - E Sta . jamaicensis A - E D2 or c ) comprise Stem . maritima [ 0047 ] i) at least one plant extract having anti - inflamma C - E /D1 - E Bur. simaruba / A - E D2 Stem . maritima tory efficiency and at least one plant extract having A - E /D2 Bid . alba / B - E D1 antimicrobial efficiency, Aloe vera B - E / D2 Sta . jamaicensis / C - E D1 [ 0048 ] ii ) at least one plant extract having anti - inflamma Aloe vera tory efficiency and antimicrobial efficiency at the same C - E /D2 Bur. simaruba / A - E D1 time, Aloe vera [0049 ] iii) at least one plant extract having anti- inflamma Wherein A = genus Bidens, B = genus Stachytarpheta , C = genus Bursera , D1 = genus tory efficiency and antimicrobial efficiency at the same Stemodia , D2 = genus Aloe and E = ethanolic extract. time and at least one further extract of a biologically active plant d ) , [0054 ] The amount of the at least one plant extract from a ), b ), and /or c ), and , optionally , d ) is greater than or equal to wherein ethanol extracts , greater than or equal to 70 % 1 % by weight preferably to less than or equal to 50 % by ethanol, and , in particular after drying , having a residual weight, preferably greater than or equal to 3 % by weight, content of ethanol less than or equal to 5 % , less than or equal greater than or equal to 5 % by weight , greater than or equal to 1 % , particularly preferably less than or equal to 0 . 1 % , are to 7 % by weight to each less than or equal to 50 % by weight, respectively preferably used in each case . The implementa based on the respective dry weight (ad 100 % by weight) , tions described above concerning the ingredients of the wherein the total content of the at least one plant extract or several plant species apply correspondingly herein . of the combination of a ) , b ) , and / or c ) preferably is greater [0050 ] Preferred formulations of the phyto -mixture than or equal to 3 % by weight, based on the total content of described above and its combinations comprise tea , tincture , the phyto -mixture (ad 100 % by weight) , greater than or solution , dispersion and suspension , powder and semi- solid equal to 5 % by weight, greater than or equal to 7 % by weight forms, such as ointments , creams and pastes . Tea according to less than or equal to 50 % by weight, preferably less than to the invention is based on at least one dry and ethanol- free or equal to 30 % by weight. In the case of adding a d ) Aloe plant extract from a) , b ), and /or c ) and , optionally , d ). extract (D2 ) , the amount of D2 is preferably greater than or [0051 ] Species of genus Stemodia ( = D1) are used as equal to 5 % by weight, greater than or equal to 10 % by further d ) biologically active plant within the meaning of the weight, greater than or equal to 15 % by weight, greater than invention . These had formerly been assigned to the Scro or equal to 20 % by weight, to each less than or equal to 70 % phulariaceae family and are nowadays assigned to the Plan by weight. The amounts of the other plant extracts a ) , b ), taginaceae family belonging to the order Lamiales . Genus and / or c ) are correspondingly low (Example 8b ) . The pre Stemodia ( Stem . ) comprises about 40 species comprising ferred amounts described herein apply correspondingly for Stem . maritima , Stem . lantana and Stem . durantifolia , which the compositions and formulations described in the follow are used in the meaning of the invention . Stem . maritima is ing. particularly preferred . [0055 ] In the case of combining two plant extracts , ratios [ 0052 ] Species of genus Aloe (= D2 ) assigned to the of 1 : 1 mixtures are preferably made , as also analysed in the Asphodeloideae subfamily which belongs to the Xanthor following examples 2 to 8 . Where two plant extracts are rhoeaceae family are used as further d ) biologically active combined , ratios may variably adjusted between 1 : 10 to plant. Genus Aloe comprises about 500 species . Aloe vera , 10 : 1 . In the case of three or more plant extracts , ratios of Aloe barbadensis , Aloe albiflora , Aloe perfoliata , Aloe vul 1 : 1 : 1 etc . are used . Proportions may variably adjusted , garis , Aloe indica and / or Aloe chinensis are preferably used depending on availability of the material and tolerability of according to the invention . Aloe vera is particularly pre - the patient to the respective extract . Thus , in the case of an ferred , with or without anthraquinones. allergy to one of the plants described herein or intolerability [ 0053] A mixture of each a plant extract from a ) Bid . alba , to one of the ingredients described above, the plant/ ingre Bid . pilosa , b ) Sta . jamaicensis , Sta . cayennensis, Sta . dient may be excluded from the phyto -mixture . The content indica , and /or c ) Bur. simaruba , Bur. microphylla , Bur. of the other plant extracts may be correspondingly adjusted glabrifolia , and , optionally , d ) an Aloe species (D2 ) , pref to achieve the desired efficiency . erably Aloe vera , exhibits particularly good efficiency in [ 0056 ] A further subject matter of the present invention is topical application on the skin , mucous membrane and oral the immunologically active phyto -mixture according to the mucosa , in particular for prevention and treatment of efflo invention comprising at least one plant extract which exhibit rescences within the meaning of the invention . Table la antimicrobial, preferably antibacterial and/ or antimycotic summarizes appropriate combinations of preferred species. efficiency against transient skin flora and /or anti- inflamma US 2018 /0036360 A1 Feb . 8 , 2018

tory efficiency. Preferably , the phyto -mixtures according to basale ) , dermis comprising Stratum paillare and Stratum the invention exhibit efficiency against transient skin flora reticulare and / or of the subcutis comprising connective and anti -inflammatory efficiency at the same time. tissue with fibroblasts , endothelial cells, collagen and fat [0057 ] Within the meaning of the invention , “ antimicro cells . bial efficiency " comprises inhibition and reduction of the [0063 ] Consequently , transient skin flora comprises, reproductivity , ability to divide and reproduction of micro according to the invention , disordered skin flora comprising organisms up to the inactivation or killing of microorgan at least one of the afore -mentioned germs phenotypically isms. “ Antimicrobial” comprises at least antibacterial causing efflorescences of at least one of the afore -mentioned ( against gram - positive and - negative bacteria ) and , prefer tissues on the skin and oral mucosa . ably , additionally antimycotic (against fungi and yeasts ). [0064 ] Physical influencing factors comprise the afore Antimicrobial efficiency further comprises inhibition of the mentioned disruptions and impairments of the skin structure biosynthesis apparatus of microorganisms, such as, for and comprise injuries , stings, cuts , scratches , abrasions, example, of the synthesis of toxins, pathogenicity factors burns or chemical burns at least of the epidermis comprising and other physiological reacts or of compounds triggering an Stratum corneum , Stratum lucidum , Stratum granulosum , immune response . Toxins comprises exotoxins and endo Stratum spinosum , Stratum basale and / or Stratum germina toxins , in particular exotoxins, such as the fungal toxins tivum ( = Stratum spinosum + Stratum basale ) , optionally of aflatoxin oder exofilantin A and B of Staphylococcus aureus . the dermis comprising Stratum paillare and Stratum reticu [0058 ] Preferably , “ antimicrobial efficiency ” comprises at lare and /or of the subcutis comprising connective tissue with least one efficiency analogous to antibiotics , in particular to fibroblasts , endothelial cells , collagen and fat cells . a lesser extent and , preferably , having less or no side effects [0065 ] In a particular embodiment of the present inven compared to synthetic antibiotics. tion , the immunologically active phyto -mixture according to 10059 ] Within the meaning of the invention , “ transient the invention comprising at least one plant extract according skin flora ” means a microbiological flora on / in the skin to the invention a ) , b ) , and /or c ) and , optionally , d ) having and/ or mucosal membrane , which , due to impact of miscel an antimicrobial, preferably antibacterial , efficiency against laneous influencing factors , may cause an efflorescence , transient skin flora , wherein the transient skin flora com results in an efflorescence or may impair further tissues by prises staphylococcus, streptococcus, methicillin - resistant systemic spread . Staphylococcus aureus (MRSA ), pseudomonads and /or 10060 ] The skin flora of healthy skin comprises a " resident acinetobacteria . skin flora ” which is also referred to as physiological, endog [0066 ] In a particular embodiment of the present inven enous skin flora or “ localised flora” . “ Resident skin flora " tion , the immunologically active phyto - mixture according to comprises germs , not impairing the healthy organism , com the invention comprises at least one plant extract exhibiting prising staphylococcus, in particular Staphylococcus epider antibacterial efficiency against at least one of the afore mis, propioni- , myco - and corynebacteria . Said germs pref mentioned germs of a transient skin flora at a concentration erably multiply in Stratum corneum and constitute a greater than or equal to 10 ug /ml to less than or equal to 10 protection flora against pathogenic and foreign microorgan mg/ ml measured as minimal inhibitory concentration (MIC ) isms. The composition of resident skin flora may be variable and / or as minimum bactericidal concentration (MBC ) of the for various skin regions, such as face, hands, feet , outer ear, respective plant extract or the extract mixture. Preferably , as well as lips and oral mucosa , the skin of the eye , in the at least one plant extract exhibit antibacterial efficiency particular the cornea , conjunctiva and mucous membrane of at a concentration greater than or equal to 10 ug /ml to less the eye . than or equal to 10 mg/ ml, greater than or equal to 10 ug /ml [0061 ] Transient, thus temporary , skin flora comprising to less than or equal to 8 mg/ ml , greater than or equal to 100 pathogenic germs is to be differentiated thereof. Pathogenic ug / ml to less than or equal to 8 mg/ ml, greater than or equal germs comprise gram -negative cocci, such as Neisseria , to 250 ug /ml to less than or equal to 8 mg/ ml , preferably gonococcus, meningococcus, gram -positive cocci , such as greater than or equal to 500 ug /ml to less than or equal to 8 staphylococcus , streptococcus , in particular Streptococcus mg/ ml , in particular greater than or equal to 10 ug /ml to less aureus, micrococcus, enterobacteria , pneumococcus and than or equal to 6 mg/ ml , greater than or equal to 100 ug/ ml Clostridia , gram -negative rods, such as Bordetella , Campy to less than or equal to 6 mg/ml , greater than or equal to 250 lobacter , Haemophilus , Heliobacter, Legionella , Salmo ug /ml to less than or equal to 6 mg/ ml , greater than or equal nella , Shigella , Vibrio , Yersinia , Escherichia coli , Kleb to 500 ug/ ml to less than or equal to 6 mg/ ml , greater than siella , Proteus and pseudomonads, gram -positive rods, such or equal to 10 ug/ ml to less than or equal to 4 mg/ml , greater as Bacillus , Clostridium , Corynebacterium , Listeria and than or equal to 100 ug /ml to less than or equal to 4 mg/ml , mycobacteria and /or yeasts , fungi, Candida und / oder greater than or equal to 250 ug/ ml to less than or equal to 4 viruses . mg/ ml , greater than or equal to 500 ug/ ml to less than or [ 0062 ] Healthy skin flora may be impaired by different equal to 4 mg/ml . influencing factors , such as physical, chemical, pathogenic [0067 ] In a particular embodiment, the phyto -mixture and endogenous physiological influencing factors and merge according to the invention with the subsequent preferred into a transient skin flora . In particular, foreign germs or combinations of plant extracts exhibits antimicrobial , pref pathogenic germsmay disrupt or displace healthy skin flora erably antibacterial, efficiency at a concentration greater thus multiplying and spreading, which finally results in a than or equal to 100 ug/ ml to less than or equal to 10 mg/ ml skin disease . In particular diseases of the cutis , preferably of (MIC and / or MBC ) comprising the epidermis , comprising at least one alteration of at least [0068 ] i ) Sta . jamaicensis , cayennensis and / or indica and one tissue selected from Stratum corneum , Stratum lucidum , Bid . alba and /or pilosa Stratum granulosum , Stratum spinosum , Stratum basale (0069 ] ii ) Sta . jamaicensis , cayennensis and / or indica and and / or Stratum germ inativum (= Stratum spinosum + Stratum Bur. simaruba US 2018 /0036360 A1 Feb . 8 , 2018

[0070 ] iii) Sta . jamaicensis and / or indica and Bur. ents : flavonoids, saponins, iridoids, phenolic acids, polyphe simaruba , Bur. microphylla and Bur. glabrifolia and Bid . nols , polysaccharides , glycosylates, terpenes , monoterpenes, alba and / or pilosa and sesquiterpene lactones , proazulenes , sulfides , carotinoides , [0071 ] iv ) i) , ii ) or iii ) and an Aloe species, respectively , vitamins ABCDE, amino acids, and /or minerals . Particu and , optionally, Stemodia maritima. larly preferably , ethanolic , dried plant extracts of a ) Bid . 10072 ] The afore -mentioned phyto -mixtures exhibit sur alba , Bid . pilosa , b ) Sta . jamaicensis , Sta . cayennensis, Sta . prisingly good efficiencies against MRSA as it is shown in indica , c ) Bur. microphylla , Bur. glabrifolia , Bur. simaruba Example 7 ( Table 5a and 5b ) . Antibacterial efficiency has and /or d ) Stem . maritima have one of the afore -mentioned surprisingly been detected for chosen species a ) , b ) , and c ) compounds. of the plant extracts according to the invention . The same [0078 ] In a particular embodiment of the immunologically applies for the other species , according to the invention , of active phyto - mixture according to the invention , it com genus a ) Bidens, b ) Stachytarpheta , and c ) Bursera . prises at least one plant extract selected from a ), b ) , and / or [0073 ] The immunologically active phyto - mixture accord c ), and , optionally, d ) which comprises at least one of the ing to the invention , comprising at least one of the plant antimicrobially , preferably antibacterially , effective com extracts according to the invention a ), b ), and / or c ) described pounds verbascosides , flavonoids, glycosides, phenyletha above exhibits anti - inflammatory efficiency at less than or noid glycosides , phenylpropanoid glycosides and / or anthra equal to 200 + 10 ug /ml , preferably at less than or equal to quinones. Preferably, the afore -mentioned phyto -mixture 180 : 10 ug/ ml , less than or equal to 160 + 10 ug /ml , less than comprises at least one plant extract from b ) St. jamaicensis , or equal to 140 - 10 ug /ml , less than or equal to 130 - 10 Sta . cayennensis, Sta . indica , a ) Bid . alba and / or Bid . pilosa . ug/ ml , particularly preferably at less than or equal to 120 : 10 [0079 ] In a further embodiment of the immunologically ug/ ml measured as IC50 of 5 -LOX inhibition of the respec active phyto -mixture according to the invention , it com tive plant extract or the extract mixture . Particularly pre prises at least one plant extract selected from a ) , b ) , and /or ferred embodiments exhibit anti - inflammatory efficiency at c ), and , optionally , d ) which comprises at least one of the less than or equal to 100 - 10 ug /ml , preferably at less than anti- inflammatorily effective compounds verbascosides, fla or equal to 90 : 10 ug /ml , less than or equal to 80 : 10 ug/ ml , vonoids, iridoids , ipolamiides, fulvoipolamiides, sesquiter less than or equal to 70 + 10 ug /ml and less than or equal to pene lactoses and or proazulenes . Preferably , the afore 60 + 10 ug /ml or less than or equal to 50 + 10 ug /ml . Particu mentioned phyto -mixture comprises at least one plant larly preferably , the at least one plant extract exhibits extract from b ) St. jamaicensis, Sta . cayennensis , Sta . indica , anti - inflammatory efficiency at less than or equal to 90 : 10 a ) Bid . alba and/ or Bid . pilosa . ug /ml of the respective plant extract of the species according [0080 ] In a particular embodiment of the immunologically to the invention a ) , b ) and / or c ) . active phyto -mixture according to the invention , it com [0074 ] The immunologically active phyto -mixture prefer prises at least two of the afore -mentioned plant extracts ably comprises at least one plant extract selected from a ) selected from a ) , b ) , and /or c ) , and , optionally , d ) preferably Bid . alba , Bid . pilosa , b ) Sta . jamaicensis, Sta . indica , Sta . comprising at least one of the species b ) St. jamaicensis , Sta . cayennensis , c ) Bur. microphylla , Bur. glabrifolia and /or cayennensis and /or Sta . indica , and one of the species a ) Bid . Bur. simaruba , and , optionally , d ) as extract of the ingredi alba and / or Bid . pilosa which comprise extracts, preferably ents of the respective plant, preferably of the aboveground ethanolic extracts , of the afore -mentioned ingredients . parts of the at least one plant . Preferably , the extract com 10081 ] The plant extracts according to the invention prises ingredients of untainted , unaltered , freshly harvested described above, phyto -mixtures comprising the plant or dried plant parts comprising bark , stem , twigs , branches , extracts and embodiments according to the invention are leaves, blossoms, buds, seeds, pods, pollen , fruit organs, provided for the production as medicament, medical prod photosynthetically active parts and/ or storage organs . The uct, nutritional supplement and cosmetic . The phyto -mixture extract of dried plant parts is preferred . The advantage of an is present in different forms for these purposes . extract of dried plant parts is the absence of water , thus [0082 ] Therefore, a further subjectmatter of the invention obtaining more concentrated extracts of the respective plant. is the immunologically active phyto -mixture according to As a result , extracts having comparably higher contents of the invention , wherein the at least one plant extract a ) Bid . active compounds per measuring unit of the respective alba , Bid . pilosa , b ) Sta . jamaicensis , Sta . indica , Sta . extract are obtained . cayennensis , c ) Bur. microphylla , Bur. glabrifolia and / or [ 0075 ] Consequently , plant extracts obtained according to Bur. simaruba , and , optionally, d ) is present in the invention from dried plants have an increased amount of [0083 ] liquid form comprising solution , dispersion , sus the compounds described above , preferably at least one pension , emulsion , tincture , syrup , juice, and tea antibacterially and /or anti - inflammatorily active compound [0084 ] solid form comprising tablet , powder, powder , comprising flavonoids, terpenes, benzoids, phenylpro dragee, globules, granules and lyophilisate , in particu panoids, glycosides and verbascosides, iridoids, ipolami lar freeze -dried form , or ides, fulvoipolamiides , sesquiterpene lactones and /or proa [0085 ] as mixture comprising capsules , aerosol, spray, zulenes. emulsion , lotion , and cream . [0076 ] Within the meaning of the invention , “ ingredients ” [ 0086 ] In an embodiment of the immunologically active comprise all of the plantal biologically and / or physiologi phyto -mixture , the at least one plant extract or the phyto cally active compounds described herein . mixture according to the invention in liquid form , preferably [0077 ] In a further embodiment of the present invention , tincture , solution , dispersion and /or suspension , each alter the immunologically active phyto -mixture comprises at least natively has a pH tolerated by the skin greater than or equal one plant extract selected from a ), b ) , and /or c ), and , to 3 to less than or equal to 9 , a pH tolerated by the oral optionally , d ) which comprises each an extract of at least one mucosa greater than or equal to 6 to less than or equal to 8 , of the subsequent compounds , in particular of the ingredi a pH tolerated by the nasal mucosa greater than or equal to US 2018 /0036360 A1 Feb . 8 , 2018

5 to less than or equal to 7 , or a pH tolerated by the eye to 8 .7 , less than or equal to 8 .5 8 . 3 8 .1 7 . 9 . In particular, greater than or equal to 7 to less than or equal to 9 . respectively pH 3 . 2 3 . 4 3 .6 3 . 8 4 . 0 4 . 2 4 . 4 4 . 6 4 . 8 5 . 0 5 . 2 5 . 3 [0087 ] Subsequent to the production of the plant extract 5 .4 5 . 5 5 .6 5 .7 5 . 8 5 .9 6 .0 6 . 2 6 . 4 6 .6 6 . 8 7 .0 7 . 2 7 . 4 7 .6 7 .8 according to the invention , in particular of the phyto 8 .0 8 .1 8. 3 8 .5 or 8 . 7 . mixture , according to the method according to the invention , 10095 ] Formulations according to the invention ( Example the direct product is present in freeze - dried form , preferably 8a - b ) for application on the outer ear and ear canal, prefer as lyophilisate , after freeze - drying . Subsequently , it may be ably solution , dispersion , suspension , tincture , spray , aerosol processed into fine powders , tablets or liquid forms . and semi- solid formulations, respectively have a pH greater [ 0088 ] In an embodiment, the liquid immunologically than or equal to 3 to less than or equal to 9 , preferably greater active phyto -mixture according to the invention is present as than or equal to 4 to less than or equal to 7 . tincture , in particular as solution , suspension or dispersion , [ 0096 ] Formulations according to the invention (Example comprising 8a - b ) for application on the oralmucosa , preferably solution , [ 0089 ] greater than or equal to 1 % by weight, preferably dispersion , suspension , tincture , spray, aerosol and semi greater than or equal to 3 % by weight, greater than or solid formulations, respectively have a pH of preferably equal to 5 % by weight , greater than or equal to 7 % by greater than or equal to 6 to less than or equal to 8 , preferably weight , of at least one plant extract selected from a ) greater than or equal to 6 . 2 to less than or equal to 7 . 8 . In Bid . alba , Bid . pilosa , B ) Sta . jamaicensis , Sta . cayen particular 6 . 2 6 . 3 6 . 4 6 . 5 6 .6 6 . 5 6 .6 6 . 7 6 . 8 6 . 9 7 . 0 7 . 1 7 . 2 nensis , Sta . indica , and /or c ) Bur. simaruba , Bur. micro 7 . 3 7 . 4 7 . 5 or 7 .6 . phylla , Bur. glabrifolia , based on the total contentof the [0097 ] Formulations according to the invention for depos tincture ( T = 100 % by weight) , iting on the nasal mucosa , preferably tincture , solution , [0090 ] at least one acidifier comprising acetic acid , dispersion , suspension , spray , aerosol and semisolid formu citric acid , ascorbic acid , adipic acid , tartaric acid , lations , respectively have a pH of preferably greater than or mandelic acid , and / or malic acid , equal to 5 to less than or equal to 7 . In particular pH 5 . 1 5 . 2 [0091 ] greater than or equal to 1 % by weight, preferably 5 . 3 5 . 4 5 . 5 5 .5 5 . 6 5 . 7 5 . 8 5 . 9 6 . 0 6 . 1 6 . 2 6 . 3 6 . 4 6 . 5 6 .6 6 . 5 greater than or equal to 3 % by weight, greater than or 6 .6 6 . 7 6 . 8 6 . 9 or 7 . 0 . equal to 5 % by weight , greater than or equal to 10 % by 10098 ]. Formulations according to the invention , prefer weight, greater than or equal to 15 % by weight , of an ably solution , dispersion , suspension and tincture , for apply Aloe extract , based on the total content of the tincture ing on / in the eye, in particular on the cornea , conjunctiva ( T = 100 % by weight) , and mucous membrane of the eye , respectively have a wherein the tincture has a pH value of greater than or equal physiological pH , preferably greater than or equal to 7 to to 3 to less than or equal to 9 and the tincture is an less than or equal to 9 . In particular pH 7 . 1 7 . 2 7 . 3 7 . 4 7 . 5 aqueous / ethanolic mixture having an ethanol concentration 7 . 5 7 . 6 7 . 7 7 . 8 7 . 9 8 . 0 8 . 1 8 . 2 8 . 3 8 . 4 or 8 . 5 . greater than or equal to 70 % , based on the total composition [ 0099 ] The pH values described above and preferred pH of the tincture ( e . g . Example 8b ) . The total content of the ranges for the respective use correspondingly apply for all plant extract or of the combination of each a plant extract a ) , described embodiment of the phyto -mixture according to the b ) and / or c ), respectively , preferably is greater than or equal invention and of the formulations comprising at least one to 3 % by weight, preferably greater than or equal to 5 % by plant extract a ) , b ), and / or c ), and , optionally , d ) , without weight, greater than or equal to 7 % by weight, respectively explicitly stating it. based on the phyto -mixture (ad 100 % by weight) . [0100 ] A further embodiment of the immunologically [0092 ] All physiologically compatible , synthetic , active phyto mixture according to the invention comprises , biobased and natural acidifiers are suitable as acidifiers . In in solid form , at least one essentially at least one essentially particular , acidifiers being available as foodstuffs , such as dry , in particular solvent- free , plant extract, selected from a ) vinegar, cider vinegar , white vine vinegar, balsamic vinegar, Bid . alba , Bid . pilosa , b ) Sta . indica , Sta . jamaicensis, Sta . may be used as acidifiers . Ultrapure , pharmaceutically and / cayennensis , and / or c ) Bur. simaruba , Bur. microphylla , Bur. or cosmetically authorised acidifiers are preferably used . glabrifolia , and , optionally , d ) Stemodia maritima , and /or an [ 0093] The appropriate pH value of the respective phyto Aloe species . mixture depends on the type of indication and its adminis [0101 ] Within the meaning of the invention , “ essentially tration form . The acidifier is suitable for setting the pH dry ” means that the respective plant extract a ) , b ) , and / or c ) , value , without limiting it to this function . The pH value is and , optionally, d ) of the at least one plant has a residual greater than or equal to 3 to less than or equal to 9 , preferably moisture of less than or equal to 10 % by weight, preferably greater than or equal to 3 . 1 , greater than or equal to 3 . 2 , less than or equal to 8 % by weight, less than or equal to 5 % greater than or equal to 3 . 5 to each less than or equal to 8 . 7 , by weight, less than or equal to 4 % by weight , less than or less than or equal to 8 . 5 8 . 3 8 . 1 7 . 9 , less than or equal to 7 . 8 equal to 3 % by weight, less than or equal to 2 % by weight , and preferably less than or equal to 7 . 6 . particularly preferably less than or equal to 1 % by weight, [ 0094 ] Topical formulations, preferably solution , disper less than or equal to 0 . 1 % by weight, equal to 0 % by weight, sion , suspension , tincture , aerosol, spray and / or semi- solid based on the total weight of the respective plant extract. formulations, such as ointment, cream and paste , for appli [0102 ] Within the meaning of the invention , “ solvent cation on the skin within the meaning of the invention , free ” means a residual content of solvent less than or equal excluding oral/ nasal mucosa , eye , cornea , conjunctiva and to 10 % by weight, preferably less than or equal to 8 % by mucousmembrane of the eye , comprising the phyto -mixture weight , less than or equal to 5 % by weight, less than or equal according to the invention comprising at least one plant to 4 % by weight , less than or equal to 3 % by weight , less extract a ) , b ) , and / or c ) , and , optionally , d ), preferably have than or equal to 2 % by weight, less than or equal to 1 % by a pH greater than or equal to 3 to less than or equal to 9 , weight, particularly preferably less than or equal to 0 . 1 % by preferably greater than or equal to 3 .5 to less than or equal weight, based on the total weight of the respective plant US 2018 /0036360 A1 Feb . 8 , 2018 extract of the at least one plant, wherein solvents comprise plant parts may be performed if required . In the case of using water, 1 , 2 - propylene glycol, aqueous ethanol, ethanol, in a toxic solvent a further step for removing the solvent is particular greater than or equal to 70 % ethanol to less than preferably performed . or equal to 100 % ethanol, greater than or equal to 70 % [0117 ] In an embodiment of the method according to the ethanol, methanol, acetone , chloroform , n -butanol , hexane , invention , undesired ingredients of the respective plant ethyl acetate , diethyl ether , or a mixture of at least two of the extract according to the invention a ) , b ) , and / or c ) , and , afore -mentioned solvents . Solvents , being completely optionally , d ) are removed . Preferably , compounds with removable , in particular without harmful or irritating residu laxative effect, in particular anthraquinones, are removed for als , are preferred . oral formulations for absorption through the gastrointestinal [0103 ] A further subject matter of the present invention is tract. a method for the production of an immunologically active [0118 ] Preferably , the at least one further processing step phyto -mixture comprising at least one plant extract respec for homogenization of the obtained liquid or dry plant tively selected from the species according to the invention of extract is performed prior to mixing of the at least two plant genus a ) Bid . alba , Bid . pilosa , b ) Sta . jamaicensis , Sta . extracts or prior to the formulation into one of the admin cayennensis , Sta . indica , c ) Bur simaruba , Bur. microphylla istration forms described herein (Example 8a - b ) of the and / or Bur. glabrifolia , and , optionally , d ) Stemodia and / or phyto -mixture according to the invention . Aloe, respectively , comprising the steps of [0119 ] In the method according to the invention for the [0104 ] providing at least one plant part of at least one production of an immunologically active phyto -mixture plant selected from above - and / or underground plant comprising at least one plant extract according to the inven parts, in particular bark , stem , twigs, branches, leaves , tion a ) , b ) , and / or c ) , and , optionally, d ), extraction is blossoms, buds, seeds, pods, pollen , fruit organs, pho performed with at least one solvent, comprising water , tosynthetically active parts , storage organs and/ or root, 1 , 2 - propylene glycol, aqueous ethanol, ethanol, greater than [0105 ] at least one extraction step , in particular at least or equal to 70 % ethanol to less than or equal to 100 % one cycle of the method comprising at least one extrac ethanol, methanol, acetone, chloroform , n -butanol , hexane, tion step , at least one separating step and , optionally , at ethyl acetate , and / or diethyl ether in particular a mixture of least one drying step , and at least two of the afore -mentioned solvents . [0120 ] Aqueous ethanol greater than or equal to 70 % [0106 ] obtaining at least one plant extract, preferably in ethanol to less than or equal to 100 % ethanol is preferably dry or liquid form , and used as solvent for extraction . Due to low to no toxicity of [0107 ] optionally , a further processing step comprising ethanol, the aqueous extracts and ethanol extracts of the drying , crushing , milling by means of a mill , process species according to the invention a ) , b ) , and / or c ), and , ing in a mortar, dispersing , and /or optionally d ) are preferred in contrast to , for example 10108 ] optionally, processing into a homogenous mix methanol, acetone or chloroform . After drying , the residual ture . content of ethanol preferably is less than or equal to 5 % , [ 0109 ] In the separating step , the obtained extract is sepa particularly preferably less than or equal to 1 % , less than or rated from the remaining plant parts using the solvent, equal to 0 . 1 % of ethanol. Aqueous ethanol, ethanol, prefer preferably by filtration , thin - layer chromatography , distilla ably greater than or equal to 70 % to less than or equal to tion , shaking out or evaporation . Choice of the separating 100 % are preferred solvents. In particular greater than or step is knowledge of the person skilled in the art . equal to 75 % , greater than or equal to 80 % , greater than or [0110 ] Remaining and separated plant parts may subse equal to 85 % , greater than or equal to 90 % , greater than or quently be supplied to another extraction and be previously equal to 95 % , 96 % , 97 % , 98 % to less than or equal to 100 % crushed if required . The steps extraction , separating , option ethanol. Particularly preferably , Ultrapure and biobased ally drying of the obtained extract and crushing of separated ethanol is used . In a preferred embodiment of the method plant parts may , in a variable manner, be combined , joined according to the invention for the production of an immu with fresh plant parts and repeated . The arrangement of the nologically active phyto -mixture within the meaning of the method is knowledge of the person skilled in the art , invention , at least one plant extract a ) , b ) , and /or c ) , and, achieving maximal yield of the ingredients already optionally , d ) is obtained in liquid form , in dry form or as described above in the plant extract according to the inven mixture of solid and liquid forms. tion a ) , b ) , and/ or c ) , and , optionally , d ), and the phyto [0121 ] In context of the obtained product according to the mixture according to the invention . method according to the invention , “ mixture ” comprises dry [0111 ] Preferably , plant parts of the plants are used , and liquid ingredients extracted from the plant parts . Liquid ingredients may comprise residual moisture of the liquids selected from from the plants , oily ingredients and residual solvent. [0112 ] a ) Bid . alba, [0122 ] The method according to the invention for the [0113 ] b ) Sta . jamaicensis , and /or production of at least one immunologically active phyto [0114 ] c ) Bur. simaruba, and , optionally , mixture further comprises at least one mixing step , com [0115 ] d) genus Aloe ad /or genus Stemodia , preferably prising Stem . maritima, Aloe vera , Aloe barbadensis , Aloe [ 0123 ] i ) mixing at least two of the plant extracts accord perfoliata , Aloe vulgaris, Aloe indica and /or Aloe chin ing to the invention selected from a ) , b ) , and / or c ) , in ensis . particular in liquid form , in dry form and /or as mixture of [0116 ] One cycle of the method comprises at least one solid and liquid forms, or extraction step and at least one separating step . Optionally, [0124 ] ii ) mixing at least one of the plant extracts accord at least one drying step of the already obtained extract may ing to the invention selected from a ) , b ), and /or c ) , in be performed between cycles . Drying step of the separated particular in liquid form , in dry form and / or as mixture of US 2018 /0036360 A1 Feb . 8 , 2018

solid and liquid forms, with d ) at least one further extract solvent and this is subsequently removed and the plant of a biologically active plant, and extract is dried . In order to produce a solution , dispersion , [0125 ] in particular a step for homogenization , disper suspension or tincture , the dried and solvent - free plant sion of the at least one plant extract prior to mixing , and extract is not homogenously mixed in ethanol, but in an [0126 ] obtaining of the phyto -mixture according to the aqueous solvent without ethanol. The advantage is that no invention . irritating solvent is contained in the case of application on [ 0127 ] In an arrangement of the method according to the the skin or mucous membrane , in particular on wounds. The invention , a dried form of at least one plant extract, e . g . a “ aqueous alternative ” correspondingly applies for all for powder , with a liquid form of at least one plant extract can mulations according to the invention and indications. In be mixed . The liquid form may be , for example , an undried particular for formulations for application in the eye, on ethanol extract. The advantage is that the concentration of nasal and oral mucosa . the total plant extract per volume is not reduced by addi [0144 ] “ Aqueous solvents ” shall be understood to mean tional liquids . Moreover , purity of the extract is improved physiologically , pharmaceutically compatible solutions on since mixtures of solvents are avoided and defined concen the basis of water or physiologically compatible buffer trations and mixtures are produced . systems, in which the dried plant extracts are homogenously (0128 ] Preferably , dry forms of extracts are mixed into an mixable into a dispersion or solution . The person skilled in immunologically active phyto mixture comprising at least the art knows such “ aqueous solvents” . one plant extract according to the invention a ) , b ) , and / or c ) [0145 ] Preferably plant extracts are mixed which are and subsequently processed into a liquid form , preferably obtained by the method according to the invention from solution , solution for use as tincture, tincture , suspension plant parts of plants selected from and / or dispersion , using a solvent, preferably ultrapure etha [0146 ] a ) Bid . alba or Bid . pilosa , nol. Preferably , a phyto -mixture according to the invention [0147 ] b ) Sta . jamaicensis , Sta . cayennensis or Sta . indica , made of dry extracts according to the method according to and / or the invention is obtained , comprising [0148 ] c ) Bur. simaruba , Bur. microphylla or Bur. glabri [0129 ] providing at least one plant part, respectively , of folia , and , optionally [0130 ] a ) Bidens alba and /or Bidens pilosa , 10149 ) d ) at least one species of genus Aloe and / or Ste [0131 ] b ) Sta . jamaicensis , Sta . cayennensis and /or Sta . modia , preferably Stem . maritima , Aloe vera , Aloe bar indica , badensis , Aloe perfoliata , Aloe vulgaris , Aloe indica [0132 ] c ) Bur. simaruba , Bur. microphylla and / or Bur. and /or Aloe chinensis . glabrifolia , and , optionally , [0150 ] A further subject matter of the present invention is [0133 ] d ) an Aloe species selected from Aloe vera , Aloe an immunologically active phyto -mixture obtained by the barbadensis, Aloe perfoliata , Aloe vulgaris, Aloe indica method described above , wherein the phyto -mixture com and Aloe chinensis , prises at least one plant extract selected from the species [ 0134 ] respectively, extraction of the afore mentioned according to the invention of genus a ) Bid . alba , Bid . pilosa , plant parts of a ), b ) , and /or c ) , and , optionally , d ) using b ) Sta . jamaicensis, Sta . cayennensis , Sta . indica , c ) Bur. a described , appropriate solvent, in particular at least simaruba , Bur microphylla and / or Bur. glabrifolia , and , one extraction step and preferable each at least one optionally, d ) at least one further extract of a further bio cycle of the method , logically active plant, preferably of genus Aloe and /or Ste [0135 ] respectively obtaining at least one plant extract modia , particularly preferably Stem . maritima and /or of at of a ), b ), and / or c ), and , optionally , d ) comprising at least one Aloe species . least one appropriate solvent, and [0151 ] Explanations on ingredients, anti - inflammatory [0136 ] drying the respectively obtained plant extract, and antimicrobial , preferably antibacterial , efficiencies cor preferably by freeze - drying , respondingly apply for the method according to the inven [0137 ] optionally , repeating of the extraction step of the tion and the direct products obtained by means of the remaining plant parts method . Thus , the products obtained according to the [0138 ] optionally, a further processing step comprising described method exhibit the efficiencies described above , drying , crushing , milling by means of a mill , process as shown by examples 2 to 9 . ing in a mortar , dispersing , and [0152 ] A further subject matter of the present invention is [0139 ] mixing of the obtained , dry , preferably fine , an immunologically active phyto -mixture in the manner plant extracts a ), b ), and /or c ) , and , optionally, d ) , described above and / or produced according to the method [0140 ] obtaining of an immunologically active phyto described above comprising at least one plant extract mixture in dry form , and selected from the species respectively according to the [0141 ] adding greater than or equal to 70 % to less than invention of genus a ) Bidens, b ) Stachytarpheta , and / or c ) or equal to 100 % ethanol, preferably greater than or Bursera , and , optionally , d ) at least one further extract of a equal to 75 % , greater than or equal to 80 % , greater than further biologically active plant for use as medicament, or equal to 85 % , greater than or equal to 90 % , greater medical product, nutritional supplement, cosmetic , and /or as than or equal to 95 % , 96 % 97 % , 98 % to less than or an immunologically active addition to one of the afore equal to 100 % ethanol, particularly preferably ultrapure mentioned products . ethanol or biobased ultrapure ethanol, and 10153 ]. All described formulation according to the inven [0142 ] obtaining at least 70 % ethanolic solution , in tion are suitable as or for the production of medicaments , particular suspension , tincture or dispersion , based on medical products , nutritional supplements and cosmetics. 100 ml total volume ( ad 100 % ) , (Example 8b ) . [0154 ] “ Nutritional supplements ” preferably comply , [ 0143 ] In an alternative of the method described above , according to the invention , with EU directive 2002 /46 /EG the extraction is performed with a respectively appropriate and comprise products for increased supply of the human US 2018 /0036360 A1 Feb . 8 , 2018

body , preferably as powder , tablet or tea, each comprising abrasions of the skin surface , tearing of the skin and rough the immunologically active phyto -mixture comprising at ness each of the skin , in particular epidermis . least one plant extract according to the invention a ) , b ) , [0165 ] Pathologic efflorescences comprise skin diseases and / or c ), and , optionally , d ), or a preferred embodiment of accompanying with an inflammatory reaction of at least one the phyto -mixture . tissue of the skin and / or comprising microbial, in particular [0155 ] Within the meaning of the invention , “ medical bacterial, infection . Pathologic efflorescences are also sum products ” are the formulations described herein comprising marized as such skin alterations that originally occur as the described immunologically active phyto -mixture com cosmetic efflorescence and evolve into pathologic efflores prising at least one plant extract according to the invention cences in the course of disease , in particular through changes a ), b ), and /or c ), and , optionally , d ) for use in the prevention in the constitution of the skin cells . or treatment of human for medically therapeutic purposes . 0166 ) According to the invention , “ efflorescences ” com The medical products according to the invention preferably prise irritations and inflammations of skin and mucous comply with the directive 93 / 42 /EWG . Examples include membrane , bacterial infections, bacterial infections accom medicinal tea , drops , tincture , ointment , cream and paste panying with viral infections, mycoses , after -effects and comprising the phyto - mixture . secondary infection of infectious and parasitic diseases, (0156 Within the meaning of the invention , " cosmetics " diseases of the outer ear , Otitis externa ( H60 . , H62 . 1 , H62. 2 are topical cosmetic products for depositing on the skin ICD - 10 -GM ), abscess of the outer ear (H60 . 0 ICD - 10 -GM ), comprising the phyto -mixture according to the invention furuncle of the outer ear, local infections of skin and comprising at least one plant extract according to the inven subcutis , Impetigo ( L01. - ICD - 10 -GM ) , skin abscesses, tion a ), b ), and / or c ), and , optionally , d ). Such cosmetic furuncles and carbuncles ( L02 . - , LO2 . 0 bis L02 . 9 ICD - 10 products include cream , soap , peeling , poultice, cleansing GM ) , inflammations of the skin accompanying with pilo solution or mil , and related skin care products . nidal cyst (L05 .- ) , erythrasma (L08 . 1 ICD - 10 -GM ) , bullous [0157 ] Therefore , a further subject matter of the present dermatoses (L10 - L14 ) , dermatitis and eczemas (L20 - L30 ) , invention is a pharmaceutic or cosmetic composition com diaper dermatitis (L22 ) , allergic contact dermatitis (L23 ) , prising the immunologically active phyto -mixture according toxic dermatitis ( L24 ) , pruritus (L29 . - ), other dermatitis to the invention that comprises at least one plant extract ( L30 - to L30 .09 ) , Lichen ruber (L43 . - ) , papulosquamous according to the invention selected from a ) genus Bidens of skin diseases (L45 ) , urticaria and erythema (L50 - 54 ) , symp the Asteraceae family , b ) genus Stachytarpheta of the Ver toms affecting the skin and the subcutaneous tissue , burns , benaceae family , and /or c ) genus Bursera of the Burseraceae chemical burns , diseases of the skin and the subcutis through family , and , optionally , d ) at least one further extract of a exposure to radiation (L55 - L59 ) including sunburn , Derma further biologically active plant comprising Aloe species of titis solaris acuta 1 . to 2 . degree (L55 ) , frostbites , compli genus Aloe of the Asphodeloideae subfamily , species of cations trough medical and surgical treatment and impair genus Stemodia of the Plantaginaceae family and /or Stemo ments accompanying therewith comprising wound healing , dia maritima . Preferably , the afore -mentioned compositions scars and wounds. comprise at least one cosmetically and /or pharmaceutically [0167 ] The abbreviation “ ICD - 10 -GM ” stands for “ Inter authorised excipient. The described preferred embodiments national Statistical Classification Of Diseases And Related of the phyto -mixture and the formulations correspondingly Health Problems, 10th revision , German Modification ” apply for the pharmaceutic or cosmetic composition . (ICD - 10 -GM ) and is regularly updated . Herewith , explicit [0158 ] A further subject matter of the present invention is reference is made to this classification and to the description an immunologically active - phyto mixture , preferably a com of skin diseases and , in particular , the content of chapter XII , L00 -L59 is incorporated into the disclosure of the present position comprising the phyto -mixture , for use in the pre invention . vention or in a method for treatment of efflorescences [0168 ] Within the meaning of the invention , “ skin ” com comprising at least one plant extract according to the inven prises the skin of the limbs, of the extremities , of the joints , tion selected from of the upper head , of the head , of the outer ear , nose , nasal [ 0159 ] a ) Bid . alba, Bid . pilosa , mucosa , as well as lips and oral mucosa , and the skin of the [ 0160 ] b ) Sta . jamaicensis , Sta . cayennensis, Sta . indica , eye , in particular the cornea , conjunctiva and mucous mem and / or brane of the eye. In particular, “ skin ” comprises at least one [0161 ] c ) Bur. simaruba , Bur. microphylla and / or Bur. tissue layer comprising Stratum corneum , Stratum lucidum , glabrifolia , and , optionally , Stratum granulosum , Stratum spinosum , Stratum basale [0162 ] d ) genus Aloe of the Asphodeloideae subfamily, and /or Stratum germinativum ( = Stratum spinosum + Stratum genus Stemodia of the Plantaginaceae family , preferably basale ), optionally of the dermis comprising Stratum papil Stemodia maritima, Aloe vera , Aloe barbadensis , Aloe lare and Stratum reticulare and / or of the subcutis comprising perfoliata , Aloe vulgaris , Aloe indica and/ or Aloe chin conjunctive tissue with fibroblasts , endothelial cells , colla ensis . gen and fat cells . [0163 ] In general, “ Efflorescences” are skin alterations [0169 ] Preferably , the immunologically active phyto -mix and comprise cosmetic efflorescences occurring without ture , preferably the composition comprising the phyto health - damaging impairment of human , but are pertinent to mixture , is used for use in the prevention or in a method for psychological well- being of human , and physiologically treatment of the afore -mentioned efflorescences, wherein the pathologic efflorescence causing health - damaging impair at least one plant extract is selected from ment right up to serious and life - threatening diseases , such a ) Bid . alba , Bid . pilosa , as skin cancer, in humans and animals . b ) Sta . jamaicensis , Sta . cayennensis , Sta . indica and / or [ 0164 ] Cosmetic efflorescences comprise superficial c ) Bur. simaruba , Bur. microphylla and /or Bur. glabrifolia , scratches in the skin , in particular epidermis, irritations or a nd , optionally , US 2018 /0036360 A1 Feb . 8 , 2018 d ) an Aloe species of genus Aloe and /or of genus Stemodia , and , optionally , d ), such as ointment, paste , cream and gel, preferably Stem . maritima , Aloe vera , Aloe barbadensis , animal and vegetable fats , waxes, paraffins, starch , traga Aloe perfoliata , Aloe vulgaris, Aloe indica and / or Aloe canth , cellulose derivatives, polyethylene glycols , silicons , chinensis . A topical formulation , such as tincture , solution , bentonites, silicic acid , talcum , and zinc oxide , or mixtures suspension , dispersion , powder , ointment, paste or cream is of at least two of the afore -mentioned substances may be preferred (see Example 8a - b ) . used as excipients . [ 0170 ] Preferably , the immunologically active phyto -mix [0177 ] Excipients for powder or sprays comprising the ture for use in the prevention or in a method for treatment of immunologically active phyto -mixture from a ) , b ) , and / or c ) , efflorescences , as described above, comprises as d ) at least and , optionally , d ) comprise lactose , talcum , silicic acid , one further extract of a biologically active plant of at least aluminium hydroxide, calcium silicate , calcium and mag one Aloe species of genus Aloe comprising Aloe vera , Aloe nesium carbonate , magnesium oxide, metal soaps , cellulose barbadensis , Aloe perfoliata , Aloe vulgaris, Aloe indica or powder , pure and modified starches and polymer powder , Aloe chinensis, Aloe vera , a species of genus Stemodia polyamide powder, or mixtures of at least two of the and /or Stemodia maritima. afore -mentioned substances . Sprays and aerosols may addi [0171 ] In a preferred arrangement of use of the immuno tionally comprise common propellants , e . g. hydrochlorfluo logically active phyto -mixture according to the invention , rocarbons , propane / butane or dimethylether , wherein pref preferably of the composition comprising the phyto -mixture , erably biologically and pharmaceutically compatible for prevention or in a method for treatment of efflorescences, propellants are used . Powder preferably comprise lactose , efflorescences comprise cosmetic or pathologic efflores silicic acid , calcium silicate and / or mineral ash , e . g . from cences , skin diseases associated with the transient skin flora , grain . bacterial and / or viral infections of the skin , furunculoses , [0178 ] Solutions, dispersions, suspensions and emulsions mycoses , inflammatory reactions of the skin , impetigo , comprising the immunologically active phyto -mixture from benign and malign tumor formation , dermatoses , eczemas , a ), b ) , and / or c ), and , optionally , d ) may comprise common pruritus , psoriasis , acne , skin irritations, erythema, symp excipients , such as solvents , solubilizing agents and emul tomatical efflorescences, burns, chemical burns, frostbites, sifiers , e. g. water, ethanol isopropanol, ethylcarbonate , ethy efflorescences occurring by toxins , medicaments , drugs, lacetate , benzylalcohol, benzylbenzoate , propylene glycol, allergens , radiation and as side effect, irritations and inflam 1 , 3 - butylglycol, oils , cottonseed oil , peanut oil, maize germ mations of the skin caused by bites and stings of insects and oil, olive oil , castor oil and sesame oil, glycerin fatty acid parasites . In particular efflorescences according to ICD - 10 ester , polyethylene glycol and fatty acid esters of sorbitan , or GM . mixtures of at least two of the afore -mentioned substances . [0172 ] Efficiency of the phyto -mixture according to the [0179 ] Suspensions comprising the immunologically invention in some of the efflorescences using the formula active phyto -mixture form a ), b ), and/ or c ), and , optionally , tions according to the invention is described in Example 9 d ) comprise common excipients , such as liquid diluents , e . g . and in Table 7 , without being limited to them . water, ethanol or propylene glycol, suspension agents , e. g . 0173 ] The immunologically active phyto -mixture , pref ethoxylated isosterylalcohols , polyoxyethylene sorbitol erably the composition comprising the phyto -mixture , for ester and polyoxyethylene sorbitan ester, microcrystalline use in the prevention or in a method for treatment of cellulose , aluminium metahydroxide, bentonite , agar agar, efflorescences within the meaning of the invention prefer and tragacanth , or mixtures of at least two of the afore ably comprises at least one excipient selected from fillers , mentioned substances . accelerators for disaggregation , lubricants , disintegrants , [0180 ] Soaps comprising the immunologically active greases , release agents , glidants , solvents , emulsifiers , solu phyto -mixture form a ), b ), and /or c ), and , optionally , d ), bilizing agents , solubilizers , wetting agents , salt forming which comprise excipients , such as alkali salts of fatty acids, agents , buffer, gel forming agents , thickening agents , film salts of fatty acid semi- esters, fatty acid protein hydroly forming agents , binders , sorbents , sweeteners , colorants , sates , isothionates , lanolin , fatty alcohol, plant oils , plant plasticizers , stabilizers , matrix forming agents , polymers , extracts , glycerin , sugar, or mixtures of at least two of the acidifiers, preservatives, scents and / or retarding agents . afore- mentioned substances , are particularly well suited for [0174 ] Each formulation according to the invention (Ex daily use . amples 8a and 8b ) , preferably of the composition compris 10181 ] Preferred excipients for formulations of medical ing the immunologically active phyto -mixture , may com products in solid or liquid form for prevention or treatment prise excipients known from the state of the art. Further of efflorescences within the meaning of the invention com excipients comprise carriers , preservatives , antioxidants , prise lactose , sucrose , dextrose , mannitol, sorbitol, starch , stabilizers , vitamins , colorants , smell improving agents and gelatin , tragacanth , pectin , cellulose , methylcellulose , flavors . hydroxypropylmethylcellulose (HPMC ) , carboxymethylcel [0175 ] Flavors serve for masking a potentially unpleasant lulose sodium , ethylcellulose , hydroxypropylmethylcellu taste of the phyto -mixture , in particular of the formulation lose phthalate , cellulose acetate phthalate , polyvinylpyrroli comprising the afore -mentioned phyto -mixture . For done , polyvinylalcohol, polyacrylic acid , polyethylene example , mint, anise , fennel , menthol, caraway, medicinal glycol, polyethylene oxide , sodium dodecylsulfate , sodium honey , honey , agave juice , sugar, sugar substitute as well as acetylstearylsulfate, and / or sodium dioctylsulfosuccinate sugar replacer, propolis , and other flavors and flavourings ( also K salts, Ca salts ) . known according to the state of the art , are well suited [0182 ] Preferred excipients for tinctures, solutions, disper hereto . sions and suspensions according to the invention comprising [0176 ] In cosmetic formulations, preferably of the com the immunologically active phyto -mixture from a ) , b ) , and / position comprising the phyto -mixture , comprising the or c ) and , optionally , d ) comprise dextrose , mannitol, tra immunologically active phyto -mixture from a ), b ), and / or c ), gacanth , pectin , methylcellulose , hydroxypropylmethylcel US 2018 /0036360 A1 Feb . 8 , 2018 lulose ( HPMC ), carboxymethylcellulose sodium , [0191 ] greater than or equal to 1 % by weight, preferably polyvinylpyrrolidone , polyvinylalcohol, polyacrylic acid , to less than or equal to 50 % by weight, preferably polyethylene glycol, polyethylene oxide, sodium dodecyl greater than or equal to 3 % by weight, greater than or sulfate , sodium acetylstearylsulfate and /or Na -dioctylsulfo equal to 5 % by weight , greater than or equal to 7 % by succinate ( also K salts , Ca salts ), and , in particular for weight, of at least one plant extract selected from Bid . suspensions, also cellulose. alba, Bid . pilosa , Sta . jamaicensis , Sta . cayennensis , [0183 ] Semisolid forms ormixtures comprising the immu Sta . indica and /or Bur. simaruba , Bur. microphylla , Bur. nologically active phyto -mixture form a ) , b ) , and / or c ) , and , glabrifolia , based on the total content ( T = 100 % by optionally , d ) comprise hydroxypropylmethylcellulose weight) of the tincture , (HPMC ), carboxymethylcellulose sodium , polyethylene [0192 at least one acidifier selected from acetic acid , glycol, polyethylene oxide , sodium dodecylsulfate , sodium citric acid , ascorbic acid , adipic acid , tartaric acid , acetylstearylsulfate and /or pectin . mandelic acid and /or malic acid , [0184 ] In a particular arrangement of the immunologically [0193 ] greater than or equal to 1 % by weight, preferably active phyto -mixture according to the invention comprising greater than or equal to 3 Gew . - % , greater than or equal at least one plant extract from a ), b ), and / or c ), and , to 5 Gew . - % , greater than or equal to 7 Gew . - % , greater optionally , d ) , preferably the composition comprising the than or equal to 10 Gew . - % , to each less than or equal phyto -mixture , for use in the prevention or in a method for to 70 Gew . - % , of a d ) Aloe extract , based on the total treatment of efflorescences within the meaning of the inven content of the tincture ( T = 100 % by weight ) , and tion , the phyto -mixture according to the invention is present [0194 ] at least one excipient , as wherein the tincture has a pH value greater than or equal to [0185 ] oral formulation comprising i) solid forms, such 3 to less than or equal to 9 and the tincture is an aqueous / as tablet , powder, granules , effervescent tablet, dry ethanolic mixture, in particular a solution or dispersion , syrup , dragee, globules, capsule and lyophilisate , ii ) having an ethanol concentration greater than or equal to liquid forms, such as suspension , solution , dispersion , 70 % , based on 100 ml total volume of the tincture (ad tincture , concentrate , tea , or iii ) mixture , such as spray, 100 % ). Preferably , the tincture described above comprises or greater than or equal to 3 % by weight, greater than or equal [0186 ] topical formulation comprising i ) solid forms, to 5 % by weight, preferably greater than or equal to 7 % by such as powder , bath additive , hip bath powder , ii ) weight , total content of at least one plant extract according liquid forms, such as suspension , solution , dispersion , to the invention or combination from a ), b ) and / or c ) , and tincture , tea , or iii ) mixture , such as spray, aerosol, preferably greater than or equal to 15 % by weight of at least lotion , semi- solid forms comprising ointments , creams one d ) Aloe extract, respectively based on the total content and pastes . the phyto -mixture ( ad 100 % by weight) . 101871. Within the meaning of the invention , tablets com [0195 ] The tincture , solution , suspension , dispersion and prise simple tablets , lozenges , sublingual and buccal tablets , semi-solid forms described above has preferred pH values , oral dispersible tablets , solution tablets , microtablets , chew depending on its respective indication , which has been able tablets and effervescent tablets , spot tablet, scaffold described in detail in connection with the acidifiers above . tablet and multi - layer tablet, dragees and pellets. In the case [0196 ] Within the meaning of the invention , “ aqueous/ of dissolution in mouth and oral mucosa the pH value ethanolic mixture ” comprises solutions and dispersions preferably is in the described pH ranges . comprising insoluble ingredients and particles . Presence of [ 0188 ] In context of a formulation ( Example 8a and 8b ) , the aqueous/ ethanolic mixture depends on solution behavior mixtures comprise semi- solid forms. Semi- solid forms of of the extracted ingredients, the separating step and depends medicaments and cosmetic products include ointment -like on ethanol concentration . preparations, characterised by having limited form stability . [0197 ] The immunologically active phyto -mixture com Ointments and creams include all spreadable preparations prising at least one plant extract according to the invention being applied on the skin or mucous membrane . Depending from a ), b ) , and /or c ) , and , optionally , d ) , preferably the on character , semi- solid forms are distinguished in oint composition comprising the phyto -mixture , for use in the ments , creams, pastes or gels . prevention or in a method for treatment of efflorescences [ 0189 ] Ointments , in narrower sense, include preparations within the meaning of the invention , wherein the oral without aqueous phase . Hydrophobic , hygroscopic and formulation ( see Examples 8a - b and 9 ) is based on a solid hydrophilic ointments are distinguished . Creams are oint form , is also preferred , wherein ments comprising an aqueous phase beside a lipid phase . [0198 ] the solid form comprises at least one dry , in Pastes are highly concentrated suspension ointments , repre particular solvent- free , plant extract selected from Bid . senting the physical- chemical transition from suspensions to alba , Bid . pilosa , Sta . jamaicensis , Sta . cayennensis , moist powders . Sta . indica , Bur. simaruba and/ or an Aloe species , [0190 ] Preferably , the immunologically active phyto -mix [ 0199 ] the at least one plant extract is contained in a ture according to the invention comprising at least one plant content of greater than or equal to 1 % by weight, extract according to the invention from a ) , b ) , and / or c ) , and , preferably greater than or equal to 3 % by weight, optionally , d ) , preferably the composition comprising the greater than or equal to 5 % by weight, greater than or phyto -mixture , for use in the prevention or in a method for equal to 7 % by weight, based on the total content of the treatment of efflorescences within the meaning of the inven solid form ( F = 100 % by weight) , tion is present as tincture , in particular as solution , suspen [ 0200 ] the residual moisture is less than or equal to 5 % sion , dispersion or in semi- solid form ( Example 9 ) , com by weight, preferably less than or equal to 1 % by prising weight and , particularly preferably , less than or equal to US 2018 /0036360 A1 Feb . 8 , 2018

0 . 1 % by weight, based on the total content of the dry [0208 ] C : Bursera simaruba (Bur . simaruba ) plant extract ( F = 100 % by weight) , and [0209 ] Leaves and branches of a 5 - to 20 -years - old tree . The harvested leaves were dried at 57° C . to 62° C . for 8 to [0201 ] at least one excipient is contained . 20 hours and subsequently stored in a cool dry place . [ 0202 ] Particularly preferred topical formulations are [0210 ] D1: Stemodia maritima ( Stem . maritima ) those for applying, depositing , massaging in , spraying on , 10211 ] Aboveground approx . 1 - year -old herb . The har dripping on and / or laying on the affected skin surface and vested herb was dried at 40° C . for 7 hours and subsequently thus for absorption of the immunologically active phyto stored in a cool dry place . 10212 ] D2: Aloe vera mixture through the skin or mucousmembrane , in particular [ 0213 ] Starting material : 500 ml of an anthraquinone - free nasal and / or oral mucosa . water extract of Aloe vera (allcura Naturheilmittel GmbH , [0203 ] Particular preferred oral administration forms of Reichenäcker 7 , 97877 Wertheim ). 20 ml of the water the phyto -mixture according to the invention comprising at extract were freeze -dried (Christ LMC -1 , Delta 1- 20 KD ) . least one plant extract according to the invention a ), b ), Yield : dry weight 450 mg powder (about 22. 5 mg/ ml ) . and /or c ), and , optionally d ) comprise formulations for dissolving in a beverage and subsequent drinking , for swal TABLE 1b lowing ( e . g . as tablet) and absorption trough the gastroin testinal tract, for oral intake and disaggregation in the oral Plant material cavity or depositing on the oral mucosa and absorption Plant material as Dry weight Dry weight through the oral mucosa. Formulations for absorptions powder after crushing water extract ethanol extract through the gastrointestinal tract preferably comprise no Plant [ g ] [ g ] [ g ] anthraquinones since they can have a laxative effect. For 31. 5 0 . 931 1 . 464 38. 7 0 . 7275 2 .485 mulations according to the invention for indications where 33. 1 1 . 1212 5 . 8 laxative effect is desired preferably comprise no Aloe extract D1 38 . 7 0 . 299 1 . 39 or anthraquinone - free Aloe extract . The same applies for the D2 0 .450 species according to the invention of genus a ) Bidens , b ) Stachytarpheta and c ) Bursera. [ 0204 ] The following examples elucidate the invention in Example 2: Crushing of the Plant Material more detail and only represent chosen embodiments , with [ 0214 ] The plant material described above with the out limiting thereto . For this purpose , some species accord described plant parts were provided , crushed and pulverized ing to the invention were used as representatives of the in a commercial blender for about 2 minutes . Subsequently , respective genus a ) Bidens, b ) Stachytarpheta and c ) Burs the respective powder was processed into , on the one hand , era and for the species of the respective genus , described as an aqueous and , on the other hand , an ethanolic extract. being preferred . Example 3 : Production of an Aqueous Plant Extract EXAMPLES [ 0215 ] A Bidens alba - Aqueous Extract : [0216 ] The powder was transferred into a three -necked flask with distilled water ( 8 . 2 g powder to 120 ml distilled Example 1 : Source of the Used Plant Material water ) and stirred at 40° C . for twice 4 hours each or 8 hours in all. A clear solution was obtained after subsequent filtra [ 0205 ] The plants Bur. simaruba , St. jamaicensis , Bid . tion of the extract. The clear solution was freeze - dried for 64 alba and Stem . maritima disclosed and claimed within this hours (Christ LMC - 1 , Delta 1 - 20 KD ) . Yield after freeze patent application were respectively obtained from the drying : 0 . 931 g Bahamas , Isle “ Long Island ” , as representatives according to [0217 ] B Stachytarpheta jamaicensis - Aqueous Extract : the invention of genus a ) Bidens , b ) Stachytarpheta , c ) [0218 ] 8 . 0 g of the powder of Stachytarpheta jamaicensis Bursera , and d ) Stemodia . The Bahamian government issued were analogously processed to Bidens alba . Yield after appropriate certificates for harvest of the plants used herein freeze - drying : 0 .7275 g and their export to Germany for research and experimental [0219 ] C Bursera simaruba - Aqueous Extract : purposes (“ Plant Protection Service of the Bahamas” Nr. [0220 ] 8 . 2 g of the powder of Bursera simaruba were 2928 and Nr. 2929 and “ Permit to conduct Scientific analogously processed to Bidens alba . Research in the Bahamas” ) . The experiments described [0221 ] Yield after freeze - drying: 1 . 1212 g subsequently were performed within the scope of this 102221 D1 Stemodia maritima — Aqueous Extract: research permit and export authorization . [0223 ] 8. 1 g of the powder of Stemodia maritima were [ 0206 ] A : Bidens alba ( Bid . alba )/ B : Stachytarpheta analogously processed to Bidens alba . jamaicensis (Sta . jamaicensis ) [0224 ] Yield after freeze - drying : 0 . 299 g [ 0207 ] Aboveground plant parts comprising stem , leaves, shoots and blossoms each were freshly harvested from Example 4 : Production of an Ethanolic Plant young 1 - to 3 - years - old plants ( A and B ). These were dried Extract at 40° C . to 55° C . for 6 to 20 hours and subsequently stored [0225 ] A Bidens alba — Ethanol Extract : in a cool dry place . Duration of drying and temperature is [0226 ] The powder ( 8 . 0 g ) was filled into an extraction variably freely selectable according to the knowledge of the sleeve (Macherey & Nagel ; MN 645 ; 23x100 mm ) and person skilled in the art. extraction with reflux was performed using a Soxhlet extrac US 2018 /0036360 A1 Feb . 8 , 2018 14 tion with 280 ml 96 % ethanol at room temperature for 8 DMSO ( 10 minutes shaking ) , absorption at 570 nm was hours . The organic phase was filtrated through glass wool measured ( by means of Tecan Safire II Reader , Tecan ( company Migge No. 1408 / 3 ) . Subsequently , the ethanol Crailsheim , Germany ) . Doxorubicin was measured as ref extract was evaporated until dryness using a Rotavapor e rence . Cell vitality was determined according to the fol (Heidolph ; 50° C . water bath temperature, 112 bar) . Yield : lowing formula : 1 .464 g dry weight [0227 ] The dry weight was dissolved in 15 ml Ethanol in order to detach dry residues adhering to the bottom of the [( OD sample of untreated HaCaT - cells ) – round - bottom flask . Subsequently , the solution was divided to sample containers for storing at - 20° C . and dried by Vitality [ % ] = (OD sample medium control) ] * 100 blowing through of nitrogen gas. [( OD untreated HaCaT- cells) – (OD medium control) ] [0228 ] B Stachytarpheta jamaicensis - Ethanol Extract : [0229 ] 8 . 0 g of the powder of Stachytarpheta jamaicensis [0244 ] Statistical Analysis were analogously processed to Bidens alba . Yield : 2 .485 g [0245 ] Three - fold determination ( n = 3 ) with three - fold dry weight replicate was performed and the results were stated as [ 0230 ] C Bursera simaruba - Ethanol Extract: means standard deviation . IC 50 -values were calculated [0231 ] 8 .2 g of the powder of Bursera simaruba were through the dose response curve which was created by use analogously processed to Bidens alba . of a logistic regression curve with 4 parameters with the [0232 ] Yield : 5 .8 g dry weight GraphPad Prism® 5 .01 Software or SigmaPlot® 11 . 0 . The [ 0233 ] D1 Stemodia maritima - Ethanol Extract : individual curves are not shown herein . The determined [0234 ] 6 . 7 g of the powder of Stemodia maritima were IC 50 - values with standard deviations are summarized in analogously processed to Bidens alba . Tables 2 and 3 . [ 02351. Yield : 1 . 39 g dry weight [0246 ] Results [0236 ] The residual content of ethanol of the above etha [0247 ] None of the aqueous extracts Bid . alba ( A - W ) , Sta . nol plant extracts was less than 0 . 1 % . jamaicensis ( B - W ) , Bur. simaruba ( C - W ) , Stem . maritima Example 5 : Determination of Cytotoxicity of the and Aloe vera exhibits cytotoxicity compared to doxorubicin Produced Extracts as cytotoxic reference compound ( see Table 2 ) . [0248 ] Ethanolic plant extracts of Bid . alba and Bur. [0237 ] Cell Culture simaruba exhibit no cytotoxicity compared to doxorubicin [ 0238 ) HaCaT -Cells ( human in vitro spontaneous trans formed keratinocytes from histologically normal skin ) of as cytotoxic reference compound . Ethanolic extracts of Sta . DMSZ (German Collection of Microorganisms and Cell jamaicensis and Stem . maritima exhibit low cytotoxicity. Cultures ) were kept in Dulbecco ' s modified Eagle Medium [0249 ] Only the combinations with plant extracts of little (DMEM ) with glutamax ( Invitrogen /Gibco , Karlsruhe , Ger higher IC50 -values were analysed again to cytotoxicity ( see many ) with 10 % fetal calf serum (Sigma Aldrich , Germany ) , Table 3 ) . 100 U /ml penicillin and 100 ug /ml streptomycin and 1 % NEAA . Example 6 : Determination of Anti -Inflammatory [ 0239 ] The cells were cultivated at 37° C ., 5 % CO , and Activity 95 % humidity . The cells were subcultivated by removing the [0250 ] Inhibition of 5 - Lipoxygenase (5 - LOX ) through the medium , adding 0 .075 % EDTA - solution in 1 - fold PBS individual extracts and their combinations (see Table 2 and (phosphate - buffered salt solution ) and subsequently incu 3 ) was spectroscopically determined (Baylac & Racine bated at 37° C . for 10 min . EDTA was removed and the 2003 ) . For this purpose 970 ul of the phosphate buffer ( 21. 2 HaCaT - cells were detached form the culture vessel by g K3PO4 in 1 L H2O ) , pH 9 . 0 were mixed with 10 ul of 1 addition of 0 .25 % trypsin and 0 .02 % EDTA at 37° C . for 5 mg/ml concentrated 5 -LOX ( lyophilized powder, Fluka ) and min . Afterwards, addition of fresh medium , centrifugation , 20 ul various concentrations ( 0 . 48 ug /ml to 250 ug /ml ) of the exhausting of the medium and transferring in a new flask individual plant extracts and of the combinations ( 1 : 1 mix ( ratio 1 : 5 or 1 : 10 ) was done . All experiments were per ture ) . The mixture was incubated at room temperature for 10 formed using cells in the logarithmic growth phase . minutes . Enzymatic reaction was initiated by adding of 20 ul [ 0240] Sample Preparation : of 5 mM sodium linoleate (Sigma Aldrich ). Reaction kinetic [0241 ] Aqueous extracts were dissolved in water (100 was determined at 234 nm every 5 seconds by means of a mg/ ml water ) and ethanol extracts in dimethylsulfoxide , WPA Biowave II spectrophotometer. Nordihydroguaiaretic DMSO , (200 mg /ml DMSO ). acid (NDGA ) was used as positive control of a 5 - LOX [ 0242 ] MTT -Assay According to Mosmann , 1983 ( I. of selective inhibitor. Immunological Methods 65 , 55 -63 ) [ 0251 ] Initial reaction speed was respectively determined [ 0243 ] In order to determine the concentration dependent from the slope of the linear part of the curve . Inhibition of cytotoxicity 2x104 HaCa T - cells / sample well of a 96 - well the enzyme activity was calculated from three -fold experi plate were transferred and incubated for 24 hours . Incuba ments . Percentage of the initial activity was determined tion of the HaCaT -cells was performed using 100 ul of the according to the following formula : medium containing various concentrations of the respective plant extract ( see Table 2 ) or a 1 . 1 mixture of two plant [% ] of the initial activity = ( IAcontrol- IAsample) / IAcon extracts ( see Table 3 ) . Subsequently , 0 . 5 mg/ ml MTT ( 3 - ( 4 , trolx100 5 -Dimethylthiazole - 2 - yl) - 2 , 5 - diphenyltetrazoliumbromide ) wherein sample corresponds to an individual plant extract or were added and incubated for 4 hours . After dissolving the a combination of at least two plant extracts and control formazan crystals formed by the HaCaT- cells in 100 ul equals to NDGA. US 2018 /0036360 A1 Feb . 8 , 2018 15

[0252 ] Percentage [ % ] of the initial activity was (y -axis ) Example 7 : Determination of Antimicrobial graphically plotted as a function of the concentration of the Efficiency respective plant extract or the combination ( 1 : 1 mixture ), in order to determine the IC50 -value as the concentration at [0256 ] Antibacterial efficiency of the respective plant which 50 % of the enzyme activity is inhibited by the extract as individual extract and as combination of two respective plant extract or the combination . extracts was analysed against the following test germs : [0253 ] Results [ 0257 ] Gram - positive Bacteria [0254 ] Table 2 shows that ethanolic Bur. simaruba ( C - E ) extract exhibits significant inhibition of 5 - Lipoxygenase . [ 0258 ] Methicillin resistant Staphylococcus aureus Consequently , an ethanol plant extract of Bur. simaruba MRSA NCTC 10442 (MRSA NCTC 10442 ) ( C - E with IC50 = 132 - 13 ug /ml ) exhibits provably significant anti - inflammatory activity . The same applies for the respec [0259 ] Staphylococcus aureus ATCC 25923 ( S . aureus tive ethanol individual extracts of Sta . jamaicensis ( B - E ATCC 25923 ) with IC50 = 84 : 10 ug /ml ) and Bid . alba (A - E with [0260 ] Staphylococcus epidermidis ATCC 14990 ( S . IC50 = 139 : 7 ug/ ml ) . epid . ATCC 14990 ) [0255 ] Table 3 shows that the combinations of the respec [0261 ] Gram -Negative Bacteria tive extracts exhibit an increased inhibition of 5 - Lipoxy genase . These experiments respectively prove significant [ 0262 ] Pseudomonas aeruginosa ATCC 27853 ( P . anti - inflammatory efficiency for Bid . alba , Sta . jamaicensis aerug . ATCC 27853 ) and and Bur. simaruba as representatives for genus a ) Bidens , b ) Stachytarpheta and c ) Bursera . This efficiency may be [0263 ] Acinetobacter baumanii ATCC BAA747 ( ATCC attributed to the compounds, being contained in the species BAA747 ) according to the invention and being extracted by means of [0264 ] Culture Preparation the method according the invention , comprising verbasco [ 0265 ] The bacteria were precultivated on Columbia sides , flavonoids , iridoids, ipolamiides, fulvoipolamiides, medium with 5 % sheep blood at 37° C . for 24 hours . On to sesquiterpene lactones and / or proazulenes. two colonies were suspended in saline solution ( 0 . 9 % NaCl) and adjusted to a turbidity of 0 . 5 McFarland standard which TABLE 2 corresponds to 1x108 colony forming units per milliliter Individual extracts (CFU /ml ) . Subsequently , the suspension was diluted to 1x10 CFU /ml . Cytotoxicity IC50 5 - Lox- inhibition IC 50 Extract Plant [ug /ml ] [ug /ml ] [ 0266 ] Determination of the Minimal Inhibitory Concen A - W Bid . alba > 3000 > 1000 tration (MIC ) and the Minimum Bactericidal Concentration A - E Bid . alba 527 - 68 139 = 7 ( MBC) B - W Sta . jamaicensis 1023 + 153 > 1000 B - E Sta . jamaicensis 546 = 66 84 + 10 [0267 ] The MIC was determined by means of the C - W Bur. simaruba 4670 + 400 > 1000 microbouillon dilution process according to NCCLS ( 2006 ) . C - E Bur. simaruba 1800 - 670 132 + 13 For this purpose , the aqueous extracts were dissolved in D1 - W Stem . maritime 1399 = 321 > 1000 water ( w / v ) and the ethanolic extracts in 5 % DMSO ( w / v ) D1- E Stem . maritima 127 + 5 > 1000 D2 Aloe vera 3360 + 860 > 1000 with 80 mg/ ml each and Bur. simaruba as well as Aloe vera Doxorubicin 8 . 6 = 2 .03 were suspended with 160 mg/ml . The extracts and the NDGA 0 . 53 + 0 . 09 combinations ( 1 : 1 mixture ) of two plant extracts were W = aqueous extract ; E = ethanol extract, A , B , C , D1 and D2 corresponds to nomenclature respectively transferred into a sample well of a 96 -well from example 1 . plate . The individual extracts were respectively adjusted to a concentration of 4 mg/ ml to 8 mg/ ml and 0 .03 mg/ ml and the combinations to 2 : 2 mg/ ml to 0 . 3 : 0 . 3 mg/ ml . Subse TABLE 3 quently , the bacteria suspensions with about 5x10 CFU /ml in Müller Hinton medium ( Fluka ) were respectively added . Extract combinations 1 : 1 mixture The accordingly fitted 96 -well plates were incubated at 37° Extract combination cytotoxicity IC50 5 -Lox - inhibition IC50 C . for 24 hours . 1 : 1 mixture [ug /ml ] [ug / ml ] [0268 ] The MIC was determined at600 nm on the basis of A - E / B - E n . b . 52 + 1 . 3 A - E / C - E n . b . 78 + 6 the turbidity . In order to determine the MBC , 3 ul of the B - E / C - E n .b . 57 + 8 suspension of the respective sample well were spread on an A - E / D1 - E 101 15 98 + 7 . 5 full culture medium and incubated at 37° C . for 24 hours. B - E /D1 - E 117 + 8 . 7 94 + 4 . 5 The MBC was determined as lowest concentrations of the C - E /D1 - E 144 + 16 99 = 14 A - E /D2 n . b . 115 + 15 respective extract which totally kills the microorganisms. B - E /D2 n . b . 73 - 16 [0269 ] All experiments were performed as three- fold C - E /D2 2710 = 290 161 23 D1 - E / D2 128 + 13 130 + 18 determination ( Table 4 to 5 ) . The antibiotics Vancomycin Doxorubicin 8 . 6 2 . 03 (briefly : Van ) and Streptomycin (briefly : Strep ) were used NDGA J . 0 .53 + 0 .09 parallelly to each experimental approach as positive control W = aqueous extract ; E = ethanol extract, A , B , C , D1 and D2 corresponds to nomenclature for antimicrobial efficiency ( Table 5c ) . Respectively one of from example 1 . thementioned test germs was carried along with the respec tively solvent (water , DMSO ) as negative control for an US 2018 /0036360 A1 Feb . 8 , 2018

inhibiting effect by the used solvent. In comparison to the TABLE 5c growth control without any addition , no negative influence on the growth was observed for all negative controls . A Positive controls ( antimikro . effect) sterility control confirmed sterility of the used media ( data not shown ). The composition of the controls is summarized Test germ in Table 5b . MIC MBC MIC ??? [ 0270 ] Results Van ug/ ml Strep ug /ml [0271 ] Table 4a summarizes the antimicrobial activity of MRSA NCTC 10442 2 n . b. the aqueous individual plant extracts . Table 4a shows anti S . aureus ATCC 25923 0 . 5 bacterial efficiency for Sta . jamaicensis ( B - W ) and Bid . alba S . epid . ATCC 14990 -Ö 2 COCO ( A - W ). Stem . maritima (D1 - W ) exhibits higher antibacterial P . aerug . ATCC 27853 J . n . b .. efficiency compared to B - W and A - W . ATCC BAA747 64 128 NAANI + [0272 ] All the following combinations ( 1 : 1 mixture ) of the aqueous extracts exhibit the same efficiency against gram positive bacteria with MIC 2 / 2 and MBC22 / 2 : A - W / B - W , TABLE 5d A - W / C - W , B - W / C - W , C - W /D1 - W , B - W /D1 - W , A - W /D1 W , A - W /D2 , B - W / D2 , C - W /D2 , D1- W /D2 Composition of the controls [ 0273 ) Table 5a summarizes the antimicrobial activity of Growth control medium + test germ without extract/ without antibiotic the ethanolic extracts and Table 5b the combinations of the Negative control medium + test germ + solvent (water / DMSO ) without ethanolic plant extracts . The experiments clearly prove an extract/ without antibiotic antibacterial efficiency of Sta . jamaicensis and Bid . alba as Sterility control medium without further additions well as of Stem . maritima . In particular, the afore -mentioned Positive control medium + test germ + solvent (water / DMSO ) + species exhibit significant efficiency against gram - positive antibiotic ( see Table 5c ) bacteria and particularly against MRSA . TABLE 4

Antimicrobial activity of the aqueous individual plant extracts MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC Test germ C - W W B - A W - D1- W D2 Van Strep MRSA NCTC 10442 >8 >8 4 >4 >4 >4 2 4 8 >8 1 2 . n. b . S. aureus ATCC 25923 >8 >8 4 >4 >4 >4 2 4 4 >8 0. 5 0. 5 2 8 S. epid . ATCC 14990 > 8 >8 4 >4 >4 >4 N2 4 8 >8 1 2 1 8 P . aerug. ATCC 27853 > 8 > 8 >4 > 4 > 4 4 > 4 > 4 > 8 > 8 no n .b . 4 8 ATCC BAA747 > 8 > 8 > 4 > 4 > 4 > 4 > 4 > 4 8 > 8 64 128 2 4

TABLE 5a Antimicrobial activity of the ethanolic individual plant extracts MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC Test germ C - E B - E A - E D1- E D2 Van Strep

MRSA NCTC 10442 A> 8 A> 8 2 4 4 > 4 0 . 5 1 8 > 8 1 2 . n . b . S . aureus ATCC 25923 A> 8 > 8 1 4 2 4 0 . 5 1 4 > 8 0 .5 0 .5 2 8 S . epid . ATCC 14990 A> 8 A> 8 1 2 1 2 0 , 5 1 8 > 8 1 2 1 8 P . aerug. ATCC 27853 A> 8 A> 8 > 4 > 4 > 4 > 4 > 4 > 4 > 8 > 8 1 . n . b . 4 8 ATCC BAA747 8 > 8 4 > 4 4 4 2 4 8 28 64 128 2 4

TABLE 5b Antimicrobial activity of the ethanolic plant extract combinations ( 1 : 1 mixture ) MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC Test germ A - E / B - E A - E / C - E B - E /E C - C - E / D1- E B - E /D1 - E A - E /D1 - E MRSA NCTC 10442 2 / 2 > 2 / 2 > 2 / 2 > 2 / 2 2 / 2 > 2/ 2 1 / 1 2/ 2 05 / 0 . 5 1 / 1 1 / 1 2 / 2 S . aureus ATCC 25923 1 / 1 > 2 / 2 2 / 2 > 2 / 2 1 / 1 > 2 / 2 0 . 5 /0 .5 1 / 1 0 . 5 / 0 . 5 1 / 1 1 / 1 2 / 2 S . epid . ATCC 14990 1 / 1 2 / 2 1 / 1 > 2 / 2 1 / 1 2 / 2 1 / 1 2 / 2 05 / 0 . 5 1 / 1 1 / 1 2 / 2 US 2018 /0036360 A1 Feb . 8 , 2018

Example 8a : Examples Formulations [ 0274 ] Application Technical Tablets Function Acceler Pellets ator with for Homeo and Semi disaggre pathic without Hard Soft solid gation , Excipient tritur film gelatin gelatin Solu - Suspen - prepar Disinte Name ation Tea coating capsules capsules tion sion a tion Powder Filler grant

1 , 2 - Propylene = glycol

Acetyltributylcitrate = Agar agar Alkyl - 4 1 1 1 1 1 hydroxybenzoate Aluminium - fatty = acid compounds 1 1 1 Aluminium oxide / = hydroxide 1 1 1 Gum arabic Essential oils A = Bentonite Calcium carbonate - Calcium P 1 hydrogenphosphate . Carboxymethyl 1 1 cellulose sodium 1 1 1 1 1 Carotine - Cellulose Cellulose acetate phthalate Cetylalcohol Cetylstearylalcohol - Citric acid Dextrose Dibutyl/ 1 1 HP Diethylphthalate Dimethylpolysiloxane Iron oxide = Ethylalcohol i 1 1 1 Ethylcellulose Gelatine = Glycerol triacetate Glycine Glycerol - - Glycerol monostearate highly dispersed - = silicon dioxide Hydroxypropyl methylcellulose 1 1 1 1 1 1 ( HPMC ) Hydroxypropyl methylcellulose phthalate Isopropylalcohol 1 Isopropylmyristate 1 1 1 1 1 Lactose 1 Lecithin Macrogol 1000 - glycerol - monolaurate , -monostearate , -monooleate Macrogol 1500 - glycerol triricinoleate Macrogol glycerol - hydroxystearate Macrogol - stearate 400 Magnesium stearate 1 1 US 2018 /0036360 A1 Feb . 8 , 2018

-continued Maltodextrin 1 Mannitol Methylcellulose 1 Sodium 1 1 1 1 cetylstearylsulfate PPP Sodium dioctyl 1 sulfosuccinate (also k salts , Ca salts ) Sodium dodecylsulfate Sodium 1 hydrogencarbonate Oleic acid - oleylester Pectin Poloxamer Polyacrylic acid Polyethylene glycol Polyethylene oxide

Polymethacrylate A Polyoxyl 23 222 laurylether , - 20 cetostearylether, - 10 oleylether Polyoxyl 40 stearate , - 50 stearate Polysorbate 20 , 60 , 80 , 40 1 1 Polyvinylacetate 1 1 1 copolymers Polyvinylalcohol 1 1 1 1 1 Polyvinylpyrrolidone Riboflavin Castor oil Sucrose Sorbitan monooleate , - palmitate , - stearate , - trioleate , - tristearate , - laurate Sorbitol Starch 1 1 1 Starches , rice , 1 1 maize -potato - , wheat Stearic acid Stearylalcohol Talcum Titanium dioxide 1 Tragacanth =

Triacetin P Triethanol amine -PAPA = Triethylcitrate 1 1 1 Tromethamol Vaseline Tartaric acid = Urea (Urea ) Ceramides Hyaluronic acid Technical function Emul sifier, Gel Solubi forming lizing agent , Sorbent agent , Thick - (Humec Basis Lubri Solubi ening tant e . g . cant, lizer, agent , or for Grease , Solvent, Wetting Salt Film Desic powder , Release Solution agent , forming forming cant, Matrix Excipient agent, acceler- Antifoam agent, agent, respec- Sweet - Color- Plasti- forming Stabi Name Glidant ator agent Buffer Binder tively ) ener a nt cizer agent lizer 1 , 2 -Propylene glycol US 2018 /0036360 A1 Feb . 8 , 2018

- continued Acetyltributylcitrate Agar agar Alkyl- 4 hydroxybenzoate Aluminium - fatty acid compounds Aluminium oxide / hydroxide Gum arabic Essential oils Bentonite Calcium carbonate Calcium hydrogenphosphate Carboxymethyl cellulose sodium Carotine 1 Cellulose Cellulose acetate phthalate Cetylalcohol Cetylstearylalcohol 1 Citric acid Dextrose Dibutyl / Diethylphthalate Dimethylpolysiloxane 1 Iron oxide 1 Ethylalcohol Ethylcellulose Gelatine - Glycerol triacetate Glycine Glycerol - Glycerol monostearate highly dispersed 1 1 silicon dioxide - Hydroxypropyl methylcellulose ( HPMC ) Hydroxypropyl - . methylcellulose phthalate Isopropylalcohol Isopropylmyristate 1 Lactose Lecithin Macrogol - 1000 - glycerol monolaurate , -monostearate , -monooleate Macrogol 1500 glycerol triricinoleate Macrogol glycerol - hydroxystearate Macrogol stearate 400 Magnesium stearate Maltodextrin Mannitol Methylcellulose Sodium cetylstearylsulfate - Sodium dioctyl sulfosuccinate (also K salts, Ca salts ) Sodium dodecylsulfate - Sodium hydrogencarbonate Oleic acidoleylester - Pectin Poloxamer - Polyacrylic acid 1 Polyethylene glycol 1 -1 1 1 US 2018 /0036360 A1 Feb . 8 , 2018

- continued Polyethylene oxide Polymethacrylate 1 Polyoxyl 23 1 laurylether, - 20 cetostearylether, - 10 oleylether Polyoxyl 40 stearate , - 50 stearate Polysorbate 20 , 60 , 80 , 40 Polyvinylacetate = copolymers Polyvinylalcohol = Polyvinylpyrrolidone 1 Riboflavin Castor oil Sucrose = Sorbitan monooleate , -palmitate , - stearate , - trioleate , - tristearate , - laurate Sorbitol Starch Starches , rice - , maize -potato - , wheat Stearic acid Stearylalcohol 22 Talcum 1 Titanium dioxide Tragacanth Triacetin Triethanol amine Triethylcitrate Tromethamol Vaseline Tartaric acid Urea (Urea ) i 1 1 Ceramides Hyaluronic acid -

[0275 ] For example , the excipients ethyl- and methylcel [0284 ] 1 - 10 g Bidens alba ( A - E ) lulose , hydroxypropylmethylcellulose , cellulose acetate [0285 ] 1 - 40 g Aloe vera (D2 ) phthalate and hydroxypropylmethylcellulose phthalate [ 0286 ] (total weight 100 g = 100 % by weight, each based exhibit retarding properties. on the dry weight) 3 . Formula : Moisturizing Cream with A - E , B - E , C - E and D2 Example 8b Formulas [0287 ] 30 to 96 g of the base formula [0276 ] Base Formula : Moisturizing Cream [0288 ] 1 - 10 g Bursera simaruba ( C - E ) 100 g base cream DAC comprises : [0289 ] 1 - 10 g Stachytarpheta jamaicensis ( B - E ) 4 . 0 g glycerol monostearate 60 [ 0290 ] 1 - 10 g Bidens alba ( A - E ) 6 . 0 g cetylalcohol [ 0291] 1 - 40 g Aloe vera (D2 ) 7 . 5 g medium chain triglycerides (neutral oil , Miglyol 812 ) [0292 ] (total weight 100 g = 100 % by weight, each based 25 . 5 g white vaseline on the dry weight ) 7 . 0 g Macrogol 20 - glycerol monostearate 10 . 0 g propylene glycol Base Tincture D2a ( Total: 100 % by Weight Based on the Dry 40 . 0 g purified water Weight) : 1 . Formula : Moisturizing Cream with C - E , B - E and D2 [ 0277] 40 to 97 g of the base formula [0293 ] 70 % by weight of an Aloe extract (D2 ) were [ 0278 ] 1 - 10 g Bursera simaruba ( C - E ) homogenously mixed in 100 ml [ 0279 ] 1 - 10 g Stachytarpheta jamaicensis (B - E ) [0294 ] 90 % ethanol [0280 ] 1 -40 g Aloe vera ( D2 ) [ 0281 ] ( total weight 100 g = 100 % by weight , each based Base Tincture D2b ( Total: 100 % by Weight Based on the on the dry weight) Dry Weight) : 2 . Formula : Moisturizing Cream with B - E , A - E and D2 [0295 ] 30 % by weight of an Aloe extract ( D2) were [ 0282] 40 to 97 g of the base formula homogenously mixed in 100 ml [ 0283 ] 1 - 10 g Stachytarpheta jamaicensis (B - E ) [0296 ] 90 % ethanol US 2018 /0036360 A1 Feb . 8 , 2018

4 . Immunologically Active Tinctures with A - E , B - E , C - E and D2 [ 0297] 100 mlbase tincture D2a or D2b were respectively mixed with : TABLE 6 MixtureMixture 44 45 46 47 48 49 50 51 52 53 Plant (1 : 1: 1 ) (1 : 1 ) (1 :1 ) (1 : 1 ) (1 : 1 : 1 ) (1 : 1 : 1 ) ( 1: 1 : 1) (1 : 1 : 3 ) ( 3: 1 ) (1 : 3: 1 ) extract % by weight Bid . 1 1. 5 1 .5 2. 5 2 5 7 0 .5 0 0 .5 /5 alba ( A - E ) u jamaicenSta. . 1 0 1. 5 0 2 7 0. 5 1. 5 / 15 1. 5 / 15 ( B - E ) N u v simaruba ( C - E )

[0298 ] The % by weight information in Table 6 is based on extracts ( or dry extracts ) having the strongest antimicrobial the dry weight of the extracts obtained according to Example effects ( Table 5a /5b ) , or to use only one extract, e . g . A - E , 3 or 4 , preferably according to Example 4 . Depending on the ( e . g . mixture 52 or 53 ) . In contrast, in the case of strong desired indication of the skin , the pH value of the afore inflammation , e . g . eye or ear , it may advantageous according mentioned tinctures 44 to 53 was set to : to the invention to increase the content of particularly a ) tincture for the skin : pH 4 . 5 to 5 . 5 anti- inflammatorily effective extracts , e . g . A - E and / or C - E b ) tincture for the oral mucosa : pH 6 . 7 to 7 . 2 ( Table 2 and 3 ) . In this case , e . g . mixture 45 or mixture 45 c ) tincture for the eye: pH 7 . 0 to 7 . 5 having increased % by weight of each 5 - 20 % by weight of d ) tincture for the nasal mucosa : pH 5 . 5 to 6 . 5 the respective dry extract would be conceivable . In the case e ) tincture for ears : pH 5 . 5 to 6 . 1 of antimicrobial ant anti - inflammatory indication at the same [ 0299 ] The afore -mentioned mixtures and % by weight time, the appropriate combination according to the invention ratios ( Table 6 ) may vary depending on the indication . For is to be chosen depending on the therapeutic goal . example , in the case where strengthened antimicrobial effect is desired , e . g. in the case of bacterial infections of the Example 9 : Application on the Skin (mucous membrane ) skin or in the mouth ( gums) , it is advantageous according to the invention to combine the [0300 ]

Patient Symptom Phyto ( f/ m ) disease mixture Dosage Application Course 4 ( f ) Lymphedema B + C + 5 cups per day Tea, warm , 5 to 6 hours under ( re or li ) , upper arm mint ( flavor ) fresh , strong internal observation , partially forearm very green , after 2 to 3 hours approx . 2 cm more symptomatical in diameter improvement after two days : regression , tension reduction , no lymphedema anymore 2b ( m ) Dry skin , pruritus , A + B + Of approx . Tincture approx . On the same day scratch marks, C + D2 200 mg 1 -4 /day applied , relief. After 2 days urticarial ( base tincture in 5 days 2 days ? only still scratch eczema, left , D2a + 44 ) maximally still ~ 3 day. marks (crusts ) left , i . p . forearm , 50 ml used , Afterwards, but dry skin . crook of the arm . coarse partially From 5 . day still gently tiny remains creamed scratch marks , but ( dry skin ) . dry skin . 1d Oral herpes , A + B + Dropwise Tincture First, no expansion area approx . C + D2 3 - 4 /day dropwise anymore , then fast 6 x 4 mm , after (base tincture 3 - 4 /day easing of the 3 - 4 hours D2a + 51 ) applied on symptoms and of already big the oral the swelling ; swelling, blister herpes desiccation within 2 days; no inflammation anymore ; small crust which healed US 2018 /0036360 A1 Feb . 8 , 2018

-continued Patient Symptom Phyto Patient( f / m ) Sedisease rtom mixturepixture Dosage Application Course after some days through humid wound care with tincture and zinc ointment >> Aciclovir ointment functioned worse le Verrucous A + B + Dropwise Dropwise approx . Day 5 : Starting papillomas at 3 C + D2 1 - 2 /day 1 - 2 / day , treatment because areas , 5 - 12 (base tincture from day 5 of inflammation mm big , D2a + 51 ) the affected and adhesion to dermatologically area thoroughly the plaster, removed by wetted with tincture commencing Erygenum secretion on day 5 ; laser; after 2 the inflammatory days all 3 pains eased inflamed ; day quickly . On day 2 3 : plaster of the application change and first crust spraying on of formation , little skin secretion ; disinfection ; sometimes light day 4 : itching ; day 3 of inflammation the application : no increased ; secretion anymore purulent fast healing, secretion inflammation formation quickly away 18. 1 4 - 5 A + B + Dropwise Insect bites Itching eased inflammatory C + D2 several wetted with quickly ; within a insect bites , 5 - 8 (base tincture times/ day the tincture few hours to one mm big ; dark D2a + 51) several day no reddening, times a day inflammation swelling, anymore ; only itching, painful; small areas without partially swelling visible ; on secretion and day 2 of the scratch marks application totally healed 19 ( f) 38 - year old with A + B + 2 - 3 / day as A cloth was Daily improved breast cancer, C + D2 application soaked with condition , not familially (base tincture the tincture ; inflammation and predisposed ; D2a + 51) cloth laid pains eased tendency to in combination onto the quickly inflamed breast with a tea with breast as After 1 . 5 years i. a . skin Bursera simaruba application after completion of problems, ( C ) with 30 -60 treatment no breast min exposure recurrence of the reddened , time breast hardened , inflammations etc .; painful, breast cancer was inflammatory removed (Course und not known )

1 . Immunologically active phyto -mixture which exhibits 2 . Phyto -mixture according to claim 1 , characterised in antimicrobial efficiency against transient skin flora and that it further comprises: anti - inflammatory efficiency , wherein the phyto -mixture comprises at least one ethanolic plant extract selected from d ) at least one further extract of a biologically active plant a ) Bidens alba (Bid . alba ), Bidens pilosa ( Bid . pilosa ) comprising Aloe species of genus Aloe of the Aspho from genus Bidens of the Asteraceae family , and at least deloideae subfamily , species of genus Stemodia of the one further ethanolic plant extract, selected from Plantaginaceae family and / or Stemodia maritima . b ) Stachytarpheta jamaicensis ( Sta . jamaicensis ) , 3 . Phyto -mixture according to claim 1 , which comprises Stachytarpheta cayennensis ( Sta . cayennensis ) , three or more ethanolic plant extracts , selected from : Stachytarpheta indica ( Sta . indica ) from genus Stachytarpheta of the Verbenaceae family , and /or a ) and c ) and d ); c ) Bursera simaruba ( Bur. simaruba ) , Bursera micro a ) and b ) and d ) ; or phylla ( Bur. microphylla ) and Bursera glabrifolia ( Bur. glabrifolia ) from genus Bursera of the Burseraceae a ), b ) and c ) and d ), family . wherein d ) respectively is Stemodia maritima. US 2018 /0036360 A1 Feb . 8 , 2018

4 . Phyto -mixture according to claim 1 , characterised in 12 . A method for the production of an immunologically that the phyto -mixture further comprises d ) at least one active phyto - mixture according to claim 1 comprising the further plant extract of an Aloe species of the genus Aloe of steps of subfamily Asphodeloideae. providing at least one plant part of at least one plant 5 . Phyto -mixture according to claim 1 , characterised in selected from a ) and one further plant selected from b ) that the transient skin flora comprises Staphylococcus, Strep and / or c ) , respectively above - and / or underground plant tococcus, methicillin - resistant Staphylococcus aureus parts ; (MRSA ) , Pseudomonads and/ or Acinetobacteria . respectively at least one extraction step , wherein aqueous 6 . Phyto -mixture according claim 1 , characterised in that ethanol, ethanol, greater than or equal to 70 % ethanol the phyto -mixture comprises an antibacterial efficiency at a to less than or equal to 100 % ethanol is used as solvent ; concentration of greater than or equal to 10 ug/ ml to less and than or equal to 10 mg/ml measured as minimal inhibitory obtaining at least one ethanolic plant extract of the concentration (MHK /MIC ) and / or as minimum bactericidal respective plant; concentration (MBK /MBC ) of the respective extract mix optionally one further processing step comprising drying , ture . comminution , grinding using a mill , processing in a 7 . Phyto -mixture according claim 1 , characterised in that mortar , dispersing ; and the phyto -mixture exhibits an anti -inflammatory efficiency mixing at least two of the ethanolic plant extracts , one at less than or equal to 200 : 10 ug/ mlmeasured as IC50 of being selected from a ) and the at least second one of b ) 5 - LOX inhibition of the respective extract mixture . and / or c ) ; and 8 . Phyto -mixture according to claim 1 , characterised in optionally adding a third plant extract selected from b ), c ) that the phyto -mixture comprises at least one of the com and/ or d ). pounds comprising flavonoids , saponins , iridoids, phenolic 13 . Method according to claim 12 , wherein the at least acids, polyphenols , polysaccharides, glycosylases, terpenes, two plant extracts are obtained in liquid form , in dry form or monoterpenes, sesquiterpene lactones, proazulenes, sulfides , as mixture of solid and liquid forms. carotenoids, vitamins A B D E , amino acids, and/ or 14 . Immunologically active phyto -mixture according to minerals . claim 1 and /or produced according to claim 12 for use as 9 . Phyto -mixture according to claim 1 , characterised in medicament, medical product, nutritional supplement, cos that the phyto -mixture is present in metic , and / or as an immunologically active addition to one liquid form comprising solution , dispersion , suspension , of the afore -mentioned products . emulsion , tincture , syrup , juice , and tea 15 . Pharmaceutic or cosmetic composition comprising the solid form comprising tablet , powder , powder , dragee , immunologically active phyto -mixture according to claim 1 . globules , granules and lyophilisate , capsule, or 16 . Immunologically active - phyto -mixture for use in the as mixture comprising capsules , aerosol, spray, emulsion , prevention or treatment of efflorescences comprising at least lotion , and cream . one ethanolic plant extract selected from : 10 . Phyto -mixture according to claim 1 , characterised in a ) Bid . alba , Bid . pilosa of the Asteraceae family and at that the phyto -mixture in liquid form , depending on the least one further ethanolic plant extract , selected from , alternative, has a pH tolerated by the skin greater than or b ) Sta . jamaicensis, Sta . cayennensis , Sta . indica of the equal to 3 to less than or equal to 9 , a pH tolerated by the Verbenaceae family , and / or oral mucosa greater than or equal to 6 to less than or equal c ) Bur . simaruba , Bur. microphylla and / or Bur. glabrifolia to 8 , a pH tolerated by the nasalmucosa greater than or equal of the Burseraceae family. to 5 to less than or equal to 7 , or a pH tolerated by the eye 17 . Phyto -mixture for use according to claim 16 , which greater than or equal to 7 to less than or equal to 9 . comprises three or more plant extracts , selected from 11 . Phyto -mixture according to claim 1 , characterised in a ) and c ) and d ) ; that the liquid phyto -mixture is present as tincture , compris a ) and b ) and d ) ; or ing a ) , b ) and c ) and d ), greater than or equal to 1 % by weight of at least one wherein d ) respectively is Stemodia maritima ethanolic plant extract selected from a ) Bid . alba , Bid . 18 . Phyto -mixture for use according to claim 16 , charac pilosa , and one further ethanolic plant extract , selected terised in that efflorescences comprise cosmetic or patho from b ) Sta . jamaicensis, Sta . cayennensis , Sta . indica , logic efflorescences , skin diseases associated with the tran and /or c) Bur. simaruba , Bur. microphylla , Bur. glabri sient skin flora , bacterial and /or viral infections of the skin , folia , based on the total content of the tincture furunculoses , mycoses , inflammatory reactions of the skin , ( T = 100 % by weight) , impetigo , benign and malign tumor formation , dermatoses , at least one acidifier comprising acetic acid , citric acid , eczemas , pruritus, psoriasis , acne, skin irritations, erythema, ascorbic acid , adipic acid , tartaric acid , mandelic acid , symptomatical efflorescences , burns , chemical burns , frost and /or malic acid , bites, efflorescences occurring by toxins, medicaments , greater than or equal to 1 % by weight of an Aloe extract, drugs , allergens, radiation and as side effect, irritations and based on the total content of the tincture ( T = 100 % by inflammations of the skin caused by bites and stings of weight ) , insects and parasites . wherein the tincture has a pH value of greater than or 19 . Phyto -mixture for use according to claim 16 , charac equal to 3 to less than or equal to 9 and the tincture is terised in that the phyto -mixture is present as an aqueous/ ethanolic mixture having an ethanol con oral formulation comprising i ) solid forms, such as tablet , centration greater than or equal to 70 % , based on the powder, granules , effervescent tablet , dry syrup , dra total composition of the tincture. gee, globules , capsule and lyophilisate , ii ) liquid forms, US 2018 /0036360 A1 Feb . 8 , 2018 24

such as suspension , solution , dispersion , tincture , con aqueous / ethanolic mixture , having an ethanol concen centrate , tea , or iii ) mixture , such as spray , aerosol, or tration greater than or equal to 70 % , based on the total topical formulation comprising i ) solid forms, such as composition of the tincture . powder , bath additive , hip bath powder , ii ) liquid 21 . Phyto - mixture for use according to claim 16 , charac forms, such as suspension , emulsion , solution , disper terised in that the oral formulation is based on a solid form , sion , tincture , tea , or iii ) mixture , such as spray, aerosol, wherein lotion , semi- solid forms comprising ointments , creams the solid form comprises at least one dried ethanolic plant and pastes . extract, selected from Bid . alba , Bid . pilosa , and at least 20 . Phyto -mixture for use according to claim 16 , charac one further dried ethanolic plant extract, selected from terised in that the phyto -mixture is present as tincture , Sta . jamaicensis , Sta . cayennensis and /or Sta . indica , comprising Bur. simaruba and optionally Aloe, greater than or equal to 1 % by weight of at least one the at least one plant extract is contained in a content of ethanolic plant extract selected from Bid . alba , Bid . greater than or equal to 1 % by weight, based on the pilosa , and at least one further ethanolic plant extract, total content of the solid form ( F = 100 % by weight ) , selected from Sta . jamaicensis , Sta . cayennensis , Sta . the residual moisture is less than or equal to 5 % by indica and /or Bur. simaruba , based on the total content weight, based on the total content of the dry plant ( T = 100 % by weight ) of the tincture , extract ( F = 100 % by weight) and at least one acidifier selected from acetic acid , citric acid , at least one excipient is contained . ascorbic acid , adipic acid , tartaric acid , mandelic acid the at least one plant extract is contained in a content of and /or malic acid , greater than or equal to 1 % by weight, based on the greater than or equal to 1 % by weight of an Aloe extract, total content of the solid form ( F = 100 % by weight) , based on the total content of the tincture ( T = 100 % by the residual moisture is less than or equal to 5 % by weight ), and weight, based on the total content of the dry plant at least one excipient, extract ( F = 100 % by weight ) and wherein the tincture has a pH value greater than or equal at least one excipient is contained . to 3 to less than or equal to 9 and the tincture is an * * *